Stockwinners Market Radar for April 26, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EDT Sound Financial Bancorp announces stock repurchase for up $2.0M

20:05 EDT Cathie Wood's ARK Investment bought 1.3M shares of Ginkgo Bioworks today

19:30 EDT Isleworth Healthcare Acquisition announces combination agreement with Cytovia - Isleworth Healthcare Acquisition Corp. (ISLE), a special purpose acquisition company, and Cytovia Holdings, a biopharmaceutical company empowering natural killer, or NK, cells to fight cancer through stem cell engineering and multispecific antibodies, earlier announced they have entered into a definitive business combination agreement. Upon consummation of this combination, Isleworth will be renamed Cytovia Therapeutics and its common stock and warrants are expected to remain listed on NASDAQ under the ticker symbols INKC and INKCW, respectively. The combined company will continue Cytovia's operations and remain focused on developing and manufacturing complementary NK cell and NK engager antibody platforms. Cytovia operates R&D laboratories in Natick, MA and a cGMP cell manufacturing facility in Puerto Rico and has scientific partnerships with Cellectis, CytoImmune Therapeutics, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco . The combined company will be led by Dr. Daniel Teper, the Co-Founder, Chairman, and CEO of Cytovia. The transaction would value the combined company at a pro forma equity value of $602M, assuming a $10 per share price, no Isleworth stockholder redemptions and no additional financing obtained prior to the closing of the transaction. As a result of the transaction, the combined company would have up to $227M in gross proceeds from a combination of approximately $207M in cash held in Isleworth's trust account, assuming no Isleworth stockholders exercise their redemption rights at closing, and $20M from PIPE financing of new investors, and without considering the proceeds of any additional prospective financing. Proceeds from private placements, funds in Isleworth's trust account, net of redemptions, and proceeds from other prospective financings, in the aggregate amount of up to one hundred million dollars, would provide Cytovia with capital for up to two years to further develop its gene-edited iNK and Flex-NK cell engager technologies. The transaction, which has been approved by each of Isleworth's and Cytovia's boards of directors, is expected to be completed in the third quarter of 2022, subject to approval by Isleworth's and Cytovia's shareholders and satisfaction, or the waiver of, customary closing conditions identified in the business combination agreement.

18:57 EDT Charles Schwab CEO acquires 26,108 common shares - In a regulatory filing, Charles Schwab CEO Walter Bettinger disclosed the purchase of 26,108 common shares of the company on April 26 at a price of $68.5494 per share.

18:51 EDT Chipotle CEO: We've been able to navigate tricky headwinds - In an interview on CNBC's Mad Money, Brian Niccol said turnover has been the best in several years, especially at the management level. The company's culture, values, and purpose is what resonates with employees, he noted. Chipotle is trying to find ways to automate things in restaurants and make the digital experience as "frictionless as possible," he added. Niccol noted that increased food costs are "real," but rather than increase menu prices, he'd prefer to eliminate inefficiencies in the business to save money.

18:11 EDT First Bancshares raises dividend 6% to 18c - The Company announced that its Board of Directors declared a cash dividend of 18c, a 6% increase over previous quarter, per share to be paid on its common stock on May 25 to shareholders of record as of the close of business on May 10.

18:02 EDT StoneCo names two new board members - StoneCo "announced additional board changes to support the next stage of the Company's growth. The StoneCo Board has approved the appointment of two new Directors, Mauricio Luchetti and Patricia Verderesi. Mr. Luchetti has been a member of the Board of Directors of several companies and has extensive experience with People and Management. Mrs. Verderesi has over 30 years' experience in the financial markets, with strong focus on risk management. At the same time, Mateus Scherer Schwening has agreed to retire from the Stone Board and was appointed VP of Finance at StoneCo Group. The appointments of Mr. Luchetti and Mrs. Verderesi as well as the resignation of Mr. Schwening and his appointment as VP of Finance are effective immediately."

17:50 EDT Microsoft says Xbox was top seller in quarter in U.S., U.K., Western Europe

17:47 EDT F5 Networks drops 10% to $175.00 after lowering FY22 revenue growth view - The company's Q3 revenue guidance also came in below expectations.

17:31 EDT Alphabet expects meaningful increase in capital expenditures in FY22 - Says YouTube Shorts now getting 30B daily views. Says encouraged by initial advertiser feedback and results for Shorts. Says testing app install and other ads on Shorts. Says working to build monetization over time. Says consumers are watching 700M hours of YouTube TV content everyday. Says Waymo was the first company to use autonomous ride-hailing in two cities simultaneously. Says offering air raid alerts in Ukraine. Says Q1 travel searches were above pre-pandemic levels in 2019. Says retail had another strong quarter. Says YouTube advertising revenue in Q1 was $6.9B. Says reached over 135M people in December. Comments taken from Q1 earnings conference call.

17:25 EDT Quest Resource announces CFO Laurie Latham retirement and succession plan - Quest Resource Holding announced that Laurie L. Latham, Quest's CFO and Senior Vice President, informed the Company of her plans to retire, after almost ten years of dedicated and valuable service to Quest. Latham's retirement from Quest is part of an orderly succession plan. She will remain with Quest until August 31. The Company has initiated a search for her successor and appointed a search committee, which will be led by Glenn Culpepper, Member of the Board of Directors.

17:20 EDT Twitter acquisition by Musk includes $1B termination fee - According to a regulatory filing, Twitter (TWTR) said that, upon termination of the merger agreement with Tesla (TSLA) founder Elon Musk under specified limited circumstances, Twitter will be required to pay X Holdings I, the so-called "parent" in this transaction, a termination fee of $1B. Specifically, this termination fee is payable by Twitter to X because Twitter terminates the Merger Agreement to allow Twitter to enter into a definitive agreement for a competing acquisition proposal that constitutes a Superior Proposal; or X Holding terminates the Merger Agreement because the Board recommends that Twitter's stockholders vote against the adoption of the Merger Agreement or in favor of any competing acquisition proposal. This termination fee will also be payable by Twitter to Parent in the event that, generally, a competing acquisition proposal for 50% or more of the stock or consolidated assets of Twitter has been publicly announced and not withdrawn, the Merger Agreement is terminated because Twitter's stockholders fail to adopt the Merger Agreement or because Twitter materially breaches the Merger Agreement, and within twelve months of such termination of the Merger Agreement, Twitter enters into a definitive agreement providing for a competing acquisition proposal for 50% or more of the stock or consolidated assets of Twitter and such acquisition is subsequently consummated. In addition, beginning on the date of the Merger Agreement, Twitter is subject to customary "no-shop" restrictions.

17:18 EDT General Motors CFO says 'continue to see ongoing strong customer demand' - CFO Paul Jacobson says: "We recognize the consumer is facing inflationary pressures. However, we continue to see ongoing strong customer demand for our vehicles, including our refreshed full-size pickup trucks, as Mary mentioned. We were able to protect against significant plant downtime and the team worked effectively to minimize the impact of continued short-term disruptions from semiconductor and other challenges. Overall, we see the availability of semiconductors continuing to improve and are working closely with our supply chain partners to help deliver our full year total company wholesale volume goal of 25% to 30% growth." Comments taken from Q1 earnings conference call.

17:15 EDT General Motors CEO says now 'in rapid launch cycle' on EVs - CEO Mary Barra states: "We are now in a rapid launch cycle because of the investments we've made over the last several years. Taking these steps has allowed us to establish an unparalleled foundation on which to execute and scale. Because of this, our drive to produce 400,000 EVs in North America over the course of '22 and '23 is underway. For example, in the short span of time, the Chevrolet, GMC and Cadillac brands will launch 6 high-volume EV products into luxury, SUV and truck segments, all enabled by Ultium. We are also working on a fully electric Corvette, as Mark shared yesterday, as well as an electrified Corvette that will arrive next year, and I have to tell you the response has been overwhelming. So by the end of 2025, we will have installed capacity to build 1 million EVs in North America, representing approximately $50 billion in annual revenue. And we will have 3 EV programs in North America, each with annual production volumes of more than 125,000 units with opportunities to expand. This is a great start toward delivering our $90 billion of EV revenue by 2030. Cadillac will be our first all-electric brand, and its journey began last month with the production launch of the LYRIQ. Unlike all of our EV entries to date, the response has been very strong. We began taking orders for the full -- we will begin taking orders for the full range of LYRIQ models on May 19, and production at Springhill will accelerate through the second half of the year and into 2023. And I have to tell you, I was at the plant last week and the LYRIQ looks absolutely great. We will also have more affordable models that will be a major source of growth for Chevrolet and Buick. We are quickly regaining momentum with the Bolt EV and EV now that production has resumed. In fact, we plan to produce more than 50,000 Bolt EVs this year for global markets, including a record 40,000 deliveries in the U.S. The first high-volume Ultium-based SUVs for Chevrolet will launch next year. Chevrolet has already previewed the all-electric laser SS, its first fully electric SS model. We'll reveal the full vehicle in July, and it goes into production mid next year. In early fall, we will reveal the Equinox EV, and the launch is scheduled just after the Blazer EV. With a starting price of around 30,000 MSRP, the Equinox EV is a true white space opportunity for us since most affordable EVs from Chevy's competitors start at $40,000 or more. Of course, our biggest growth opportunity in North America is in trucks. We have led the industry in full-size pickup sales for the last 2 years, and we will lead in EV pickups as well. We'll do it by leveraging the capability and flexibility of our purpose-built LTM platform and decades of truck design and engineering expertise as well as extensive customer insights." Comments taken from Q1 earnings conference call.

16:55 EDT Pfizer, BioNTech ask FDA to authorize booster dose for children ages 5-11 - Pfizer (PFE) and BioNTech (BNTX) submitted an application to the U.S. Food and Drug Administration for Emergency Use Authorization of a 10-microgram booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age. The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately 6 months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-microgram two-dose primary series, which was authorized under EUA for this age group in October 2021. Data from this study demonstrated a strong immune response in this age group following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine with no new safety signals. The companies also plan to submit these data to the European Medicines Agency and other regulatory agencies around the world for authorization in the coming weeks.

16:42 EDT OneSmart announces intention to change name, ticker symbol - OneSmart announced that its board of directors resolved to change the company's name to "Meta Data Limited", subject to shareholder approval being received for the name change, and ticker symbol on the New York Stock Exchange to (AIU). Pursuant to the company's fifth amended and restated memorandum and articles of association, the name change needs to be adopted by a special resolution at a general meeting of shareholders. The shareholder meeting is scheduled to be held at 10:00 p.m., Beijing Time, on April 28 at the company's headquarters in China. If approved at the shareholder meeting, the marketplace effective date of the name change and symbol change shall be April 29.

16:39 EDT Canopy Growth expects to generate savings of $100M-$150M within 12-18 months - Canopy Growth announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to accelerate its path to profitability. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Management expects to generate cost of goods sold savings, or COGS, of $30M-$50M and reduce SG&A expenses by $70M-$100M within 12-18 months. These savings are incremental to the previously announced cost savings of $150M-$200M of which the majority have already been achieved. As a result of these strategic changes, management anticipates charges between $250M-$300M in Q4, the majority of which will be non-cash and relate to the write-down of excess inventory balances as well as "property, plant and equipment" impairments. Further, the Company expects to incur between $100M-$250M in non-cash impairment charges in Q4 largely driven by goodwill and intangible asset impairments.

16:38 EDT Valley National announces up to 25M share stock repurchase program - Valley National announced that its board approved a stock repurchase program for up to 25M shares of Valley common stock. The authorization to repurchase will expire on April 25, 2024. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternative investment opportunities. Valley's board also terminated its 2007 stock repurchase program.

16:34 EDT Canopy Growth announces cost reduction initiatives including headcount reduction - Canopy Growth announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to accelerate its path to profitability. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Aligned to Canopy Growth's FY23 strategic review, the Company is conducting the following actions: Reducing cost of goods sold in the Company's Canadian cannabis business by lowering per-gram cultivation costs through increased cultivation-related efficiencies and facility improvements; Implementing a flexible manufacturing platform inclusive of contract manufacturing for certain product formats; Rightsizing indirect costs and generating efficiencies across the Company's supply chain and procurement; Aligning selling, general and administrative costs with short-term business expectations by reducing third-party professional fees and office costs; and further streamlining the organization to drive process-related efficiencies. As a result of these challenging but necessary changes to the organizational structure, dedicated team members will be impacted as the Company operates with a reduced headcount moving forward. The Canopy Management team wishes to acknowledge the efforts of these individuals during their tenure and thanks them for their contributions to the Company.

16:31 EDT Hess announces new discoveries, raises Stabroek Block, Offshore Guyana estimate - Hess "announced an increase in the gross discovered recoverable resource estimate for the Stabroek Block offshore Guyana to approximately 11 billion barrels of oil equivalent, up from the previous estimate of more than 10 billion barrels of oil equivalent. The updated resource estimate includes three new discoveries on the block at Barreleye, Lukanani and Patwa in addition to the Fangtooth and Lau Lau discoveries announced earlier this year. "

16:29 EDT Custom Truck announces resignation of CFO Brad Meader and transition plan - Custom Truck One Source announced that Todd Barrett, Chief Accounting Officer, will be appointed interim CFO effective May 13 concurrent with the resignation of Brad Meader, the Company's existing CFO. Meader, who will remain with the Company until May 27, 2022, and will assist in the transition, informed the Company of his intention to resign for another opportunity at a private company. The Custom Truck One Source Board of Directors has initiated a search for a successor to Meader. Barrett has served as the Chief Accounting Officer of the Company since 2019. Prior to joining the Company, Mr. Barrett was at Ernst & Young LLP for more than 20 years and served as a Partner from 2008 to 2018. Barrett received a Bachelors in Business Administration from The Ohio State University.

16:25 EDT Tenable Holdings to acquire Bit Discovery for $44.5M in cash - Tenable Holdings announced that it has signed an agreement to acquire Bit Discovery. After closing, Tenable will leverage Bit Discovery's EASM solutions across its entire portfolio. Once integrated, customers will have the ability to assess the security posture of their entire attack surface and understand each of these in the context of an attack path which might exist from external systems to critical assets. Bit Discovery was founded by Jeremiah Grossman and Robert Hansen. Grossman, who also founded WhiteHat Security, has spent approximately 20 years in information security. Under the terms of the agreement, Tenable will acquire Bit Discovery for a total purchase price of $44.5M in cash, subject to customary purchase price adjustments. The acquisition is expected to close later in the second quarter of 2022, subject to the satisfaction of customary closing conditions. Bit Discovery is not expected to have a significant impact on Tenable's financial results in the second quarter. For the second half of the year, revenue is not expected to be significant, but Bit Discovery is expected to add $2M to $3M of calculated current billings, most notably in the latter part of the year, and $2M to $3M of non-GAAP net loss.

16:25 EDT Rush expects parts supply constraints to continue for remainder of year - "As we look ahead, we expect parts supply constraints to continue to impact the industry through at least the remainder of the year, but we also believe parts and service demand will remain strong throughout 2022. Additionally, we continue to expand our dedicated aftermarket sales team to support large national fleets as well as increase the size of our technician workforce. By leveraging the geographic and product breadth of our network and implementing our processes and strategic initiatives at our new locations, we believe our aftermarket results will substantially outpace the industry this year," said Rush. Commercial Vehicle Sales

16:23 EDT Matador reiterates 2022 production guidance - At April 26, 2022, Matador made no changes to its full-year 2022 guidance estimates for oil, natural gas or total oil equivalent production or capital expenditures from those originally provided on February 22, 2022.

16:23 EDT General Motors sees FY adjusted automotive free cash flow $7B-$9B

16:23 EDT CVD Equipment gets order for 9 PVT systems for high-power electronics - CVD Equipment "announced that it has received an order for nine Physical Vapor Transport, PVT, systems. The systems will be used to grow Silicon Carbide material which is subsequently processed into wafers to support high power electronics applications. The systems are scheduled to ship in the second half of 2022. This order is in addition to the order for 6 PVT tools that was previously announced in Q4 2021."

16:20 EDT Alliance Resource Partners raises quarterly distribution 40% to 35c per unit - Alliance Resource Partners announced that the Board of Directors of ARLP's general partner approved an increased cash distribution to its unitholders for the quarter ended March 31, 2022. ARLP unitholders will receive a cash distribution for the 2022 Quarter of 35c per unit, payable on May 13, 2022, to all unitholders of record as of the close of trading on May 6, 2022. The announced distribution represents a 250.0% increase over the cash distribution of 10c per unit for the quarter ended March 31, 2021 and a 40.0% increase over the cash distribution of 25c per unit for the quarter ended December 31, 2021.

16:17 EDT GM CEO Mary Barra: "Our confidence is strong as we accelerate transformation' - In a letter to shareholders, GM CEO Mary Barra said: "Our confidence is strong as we accelerate our transformation, even in the face of a challenging macro environment." Barra commented that "Launching more EVs faster is the catalyst for growth, and we are accelerating our volumes, growing to 1 million units of EV capacity in North America by the end of 2025, and expanding from there. In North America alone, we target production of 400,000 all-electric vehicles over the course of 2022 and 2023. In North America, we expect to deliver record U.S. sales for the Bolt EV and Bolt EUV in 2022, even as we service customer vehicles now that production has resumed. And between now and mid-2023, Cadillac, Chevrolet and GMC will rapidly scale production of six Ultium-based vehicles... Delivering millions of affordable EVs is a key step toward delivering on our commitment to achieve carbon neutrality in our global products and operations by 2040 and eliminate tailpipe emissions from light-duty vehicles by 2035."

16:09 EDT Microsoft reports Q3 LinkedIn revenue up 34%, Intelligent Cloud revenue $19.1B

16:08 EDT Alphabet Class A shares down 6% after Q1 earnings report - Alphabet Class A shares are down $141.50, or 6%, to $2,231.50 in after-hours trading.

16:08 EDT Ambrx Biopharma announces near term milestones - Anticipated Near-Term Milestones : Topline Phase 3 data in ACE-Breast-02 by the end of 2022; Additional Phase 1 data in ACE-Pan Tumor-01 in 2H 2022; Interim Phase 1 safety data in ARX517 for PSMA in 2H 2022; Initiate Phase 1 trial in ARX305 for RCC and other cancers in 2H 2022; and Submit IND to FDA for ARX102 in 2H 2022

16:06 EDT Alphabet authorizes repurchase of up to added $70B of shares - On April 20, the board of directors of Alphabet authorized the company to repurchase up to an additional $70B of its Class A and Class C shares in a manner deemed in the best interest of the company and its stockholders, taking into account the economic cost and prevailing market conditions, including the relative trading prices and volumes of the Class A and Class C shares. The repurchases are expected to be executed from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans.

16:06 EDT Microsoft reports Q3 Microsoft Cloud revenue of $23.4B, up 32% y/y - Going forward, digital technology will be the key input that powers the world's economic output," said Satya Nadella, chairman and chief executive officer of Microsoft. "Across the tech stack, we are expanding our opportunity and taking share as we help customers differentiate, build resilience, and do more with less." "Continued customer commitment to our cloud platform and strong sales execution drove better than expected commercial bookings growth of 28% and Microsoft Cloud revenue of $23.4 billion, up 32% year over year," said Amy Hood, executive vice president and chief financial officer of Microsoft.

16:05 EDT Alphabet CEO says Q1 saw strong growth in Search and Cloud - Sundar Pichai, CEO of Alphabet and Google, said: "Q1 saw strong growth in Search and Cloud, in particular, which are both helping people and businesses as the digital transformation continues. We'll keep investing in great products and services, and creating opportunities for partners and local communities around the world."

16:04 EDT Alphabet reports Q1 Google Cloud revenue $5.82B vs. $4.05B a year ago

15:44 EDT SpartanNash up 7% after Reuters' report of takeover interest - SpartanNash shares are up $2.51, or 7%, to $37.00 following the report.

15:36 EDT SpartanNash trading halted, volatility trading pause

15:00 EDT PTC Therapeutics granted FDA Orphan Designation for ALS treatment - The FDA said that PTC Therapeutics' treatment of amyotrophic lateral sclerosis has been granted Orphan Designation status, but not approved for Orphan Indication. Reference Link

14:10 EDT Molecular Partners notes Novartis said EUA for ensovibep may require more data - Molecular Partners (MOLN) is providing an update following comments provided by Novartis (NVS) during its quarterly earnings call today. "In the call, Novartis' CEO, Vas Narasimhan stated that Emergency Use Application, or EUA, for ensovibep, which is filed and in review with the U.S. Food and Drug Administration, may require additional clinical data to be authorized. Vas Narasimhan also noted the current omicron wave of SARS-Cov-2, and the lower incidents of hospitalization associated with it, has made clinical investigations challenging to execute in this evolving environment. Novartis is engaging with the FDA to align on a potential Phase 3 study design that could provide the additional data the agency is seeking for the EUA or full regulatory approval," according to Molecular Partners' ad hoc announcement.

13:43 EDT Travelzoo announces plans for paid, subscription-based Metaverse service - In slides for its first quarter earnings report, Travelzoo discussed entering the Metaverse via Travelzoo META, a paid subscription-based service that the company said will provide members with "exclusive access to unique and cutting-edge Metaverse travel and entertainment experiences." In the slides, Travelzoo added: "We are partnering with skilled technologists to enable us to provide high-quality experiences to our members. Many of the experiences will be browser-enabled and will not require the use of specific VR hardware. We are building Travelzoo META strategically using a phased approach to judiciously navigate the rapidly changing Metaverse environment. We will measure and assess the performance of each phase and deploy a process of continuous improvement to monitor progress and pursue next steps accordingly. Travelzoo META will be managed separately from Travelzoo's core business. Travelzoo META is being built out in a cost-efficient manner with no significant upfront investment. The cost of licenses for the experiences will be paid for by preregistrations initially, and annual subscriptions thereafter. Given the newness of the industry, we are spending additional time finalizing a few important technicalities. Contingent on the status of our technical requirements, we are now planning to launch Phase 1 in May." Reference Link

13:23 EDT 22NW says Dirtt shareholders elect entire seven-member slate to board - 22NW Fund, the largest shareholder of DIRTT Environmental Solutions with ownership of approximately 19% of the Company's outstanding shares, commented on the results announced at the Company's 2022 Annual and Special Meeting of Shareholders held on Tuesday, April 26, 2022. The voting results indicate that shareholders have elected 22NW's entire seven-member slate to DIRTT's Board of Directors. DIRTT's new Board will include Aron English, Cory Mitchell, Ken Sanders, Douglas Edwards, Mary Garden, Scott Robinson and Scott Ryan. Aron English, founder and portfolio manager of 22NW, commented: "22NW is pleased that all seven of our nominees have joined the Board at this critical point in time. Our slate's ownership perspectives and industry experience will be tremendous assets in the boardroom. Our nominees are fully committed to putting this contest behind them and immediately helping chart the right path forward at DIRTT. We thank shareholders for their support throughout this process. Now that the Company's leadership structure has been reconstituted, DIRTT should be well-positioned to begin enhancing its corporate governance and prioritizing initiatives that are most likely to unlock meaningful value for shareholders, customers and other stakeholders."

12:12 EDT YouTube expands Super Thanks to all eligible creators - In a company blog post, Samantha Stevens, YouTube product manager, paid digital goods, said, " Last year, we announced Super Thanks, the latest addition to the Supers family, which gives creators another way to earn money while also helping them deepen their connections with viewers, just like Super Chat and Super Stickers. Since introducing the feature to some creators, we've seen really great feedback and today, we're excited to share that Super Thanks is now available to all eligible creators across 68 locations in the YouTube Partner Program...Here's how Super Thanks works. Fans watching YouTube videos can purchase Super Thanks at various points between $2 and $50 to express their gratitude and show support for their favorite creators and content. They will see a fun, animated GIF right on the channel's video and, as an added bonus, get a distinct, colorful comment to highlight their purchase, which creators can heart and like. We're also thrilled to share that viewers can now customize their Super Thanks comment, which was the top request we heard since we kicked off the beta. We hope that this will drive more meaningful interactions between creators and their fans! With today's expansion, Super Thanks is now available to millions of monetizing creators in 68 countries, and is available to viewers on desktop and mobile devices. Creators can enable Super Thanks via YouTube Studio to earn a new source of revenue from videos with just one click - no extra setup work or maintenance needed." Reference Link

12:03 EDT Eagle Bancorp announces stock repurchase program up to 400,000 shares - Eagle announced that its Board of Directors has authorized repurchase of up to 400,000 shares of its common stock, representing approximately 5.0% of outstanding shares, assuming the issuance of shares pursuant to the First Community acquisition scheduled to close at the end of April. Under the plan, shares may be purchased by the company on the open market or in privately negotiated transactions. The extent to which the Company repurchases its shares and the timing of such repurchase will depend upon market conditions and other corporate considerations. The plan is expected to be in place for approximately 12 months, but may be suspended, terminated or modified by the Company's Board of Directors at any time. The plan does not obligate the Company to purchase any particular number of shares.

12:01 EDT Velo3D falls -11.1% - Velo3D is down -11.1%, or -49c to $3.91.

12:00 EDT Studio City rises 13.1% - Studio City is up 13.1%, or 59c to $5.10.

12:00 EDT Arch Resources rises 19.8% - Arch Resources is up 19.8%, or $25.94 to $157.26.

11:18 EDT Graphic Packaging 'actively' exploring options for Russia business - The company is "adhering" to all U.S. and EU sanctions.

11:14 EDT ArcelorMittal announces completion of $1B share buyback program - ArcelorMittal announced that it has completed its $1B share buyback program announced on February 11, 2022 under the authorization given by the annual general meeting of shareholders of June 8, 2021. By market close on April 25, 2022, ArcelorMittal had repurchased 31,751,960 shares for a total value of EUR 910,760,633.77, or $999,999,973.17, at an approximate average price per share of EUR 28.68.

11:08 EDT Bakkt pay now enables pay with points - Bakkt announced that Bakkt pay is "enabling a new feature for customers to pay with points - and it's officially LIVE with our partner, Wyndham Rewards (WH). With Bakkt, Wyndham Rewards Members can now use their points to pay anywhere Apple Pay (AAPL) and Google Pay (GOOGL) are accepted." "This capability is a big step forward for how brands can drive deeper engagement with their loyalty programs. Not only because of the opportunities it represents for loyalty program members, but also for the potential it offers to a broader range of hotel and travel companies, retailers, QSRs and more," the company said. Reference Link

11:04 EDT RYAH Group appoints Francois Desrosiers as CFO, corporate secretary - RYAH GROUP announced that Francois Desrosiers has been nominated as CFO and Corporate Secretary of RYAH Group Inc., subject to approval by the Canadian Securities Exchange . Desrosiers previous senior executive leadership roles include Co-Founder, President, CEO and Director of Northcore Resources Inc.; Corporate Secretary and Officer of Prime Blockchain Inc., who merged with RYAH Group; Founder President CEO and Director AntOro Resources; President CEO and Director of Melkior Resources Inc.; Founder President CEO and Director of NIKRON Technologies Inc.; and Director of Orbite Exploration VSPA.

10:31 EDT AT&T awarded $15M 11-year EIS contract for modernize GuardNet - AT&T was awarded a task order to modernize GuardNet, the command and control network that allows Army National Guard soldiers to access the Internet, connect with other networks and databases, and support training and mission planning and execution. The task order, awarded by the Defense Information Systems Agency's Defense Information Technology Contracting Organization is valued at $15M over 11 years if all options are exercised. It was awarded via the General Services Administration's Enterprise Infrastructure Solutions contract. Under the agreement, AT&T expects to deliver virtual private networking services to support the Army National Guard's remote training services and provide the Department of Defense high-speed, highly secure cloud connectivity.

10:18 EDT JetBlue sees June RASM approx. 20% year-over-three

10:16 EDT IDenta selected to supply 220,000 drug detection systems to Italy - IDenta announced that it won a tender and was selected to supply 220,000 drug test kits to the security forces of Italy. Amichai Glattstein, CEO, announced: "This is a great achievement for our company. IDenta continues to expand its activities in other countries and continues to display superiority over other competitors - both in technology and in pricing. Italy is an important European country with extensive activities in the field of drug detection and interdiction. We are very happy and excited about Italy's selection of IDenta products for their forces. We are aware of the extensive testing that was performed before this decision was made. IDenta will continue to enhance its operations in additional countries as we continue to provide unique solutions, at the highest level, for a better future and a safer world."

10:10 EDT Boeing announces 737 MAX MRO agreement with Spirit AeroSystems - Boeing Global Services (BA) announced a new agreement with Spirit AeroSystems (SPR) and its affiliates to combine aftermarket resources, expanding the MRO footprint in support of nacelle and flight control repairs for the global 737 MAX fleet. "The agreement will enhance Boeing support for nacelle and flight control surface removals with a more robust MRO footprint while combining Boeing's industry-leading asset pool with the hands-on repair experience of Spirit AeroSystems," the companies stated.

10:07 EDT JetBlue guidance does not include possible transaction with Spirit, says CEO

10:06 EDT JetBlue planning more conservatively for the summer, says CEO - Comments taken from Q1 earnings conference call.

10:04 EDT WPP appoints Kyoko Matsushita as CEO in Japan - WPP announced the appointment of Kyoko Matsushita as CEO in Japan. In this new role, Kyoko will be responsible for WPP's business in Japan, strengthening its collective capabilities and bringing together people and resources on behalf of clients. Kyoko is currently CEO for Essence Global, WPP's global data and measurement-driven full-service media agency.

10:04 EDT Bally's, Cleveland Browns enter long-term partnership - The Cleveland Browns and Bally's Interactive announced a long-term partnership that features various fan-focused elements and establishes the gaming leader as an official sports betting partner of the team. Pending appropriate licensing and regulatory approvals, the collaboration will be highlighted by a branded lounge at FirstEnergy Stadium, the launch of the mobile Bally Bet Sportsbook app in Ohio and free-to-play gaming opportunities for fans in the state. The Browns and Bally's are currently identifying the location and specific fan accommodations for the Bally-themed lounge at FirstEnergy Stadium, details for which will be finalized in the coming months. In accordance with all applicable regulations, Browns fans ages 21 and up will have the ability to enjoy an exciting collective sports betting experience within the new space on gamedays while watching on-field action from across the league. As the team's designated sports betting operator, pending appropriate licensing and regulatory approvals, Bally's will launch a mobile sports betting app for fans to place wagers on sporting events anywhere in the stadium and throughout Ohio. Additionally, the partnership will encompass a variety of fan engagement activations, including unique digital content and an engaging free-to-play predictor game, which will give registered users the opportunity to earn special Browns-themed non-cash promotional prizes.

10:00 EDT Polaris falls -9.2% - Polaris is down -9.2%, or -$9.81 to $96.97.

10:00 EDT Universal Health falls -11.4% - Universal Health is down -11.4%, or -$15.78 to $122.98.

10:00 EDT Studio City rises 13.1% - Studio City is up 13.1%, or 59c to $5.10.

09:57 EDT JetBlue: June expected to be profitable - Sees sequential CASM ex-fuel progress in 2H as JetBlue optimizes staffing levels, restores aircraft utilization, drives productivity.

09:56 EDT JetBlue sees Q2 capacity flat to up 3% vs. 2Q19, revenue up 11%-16% - Sees Q2 CASM ex-fuel up 15%-17% vs. 2Q19. Comments taken from Q1 earnings conference call presentation slides.

09:47 EDT Banco Santander falls -8.7% - Banco Santander is down -8.7%, or -29c to $3.04.

09:47 EDT Sherwin-Williams rises 8.1% - Sherwin-Williams is up 8.1%, or $20.06 to $268.08.

09:47 EDT MagnaChip rises 18.9% - MagnaChip is up 18.9%, or $2.84 to $17.87.

09:43 EDT Wipro to acquire Rizing from One Equity Partners, terms not disclosed - Wipro announced that it has signed a definitive agreement to acquire Rizing Intermediate Holdings, a global SAP consulting firm. The company said, "Rizing is the latest in a series of acquisitions by Wipro, underscoring the company's ambitious growth agenda. Rizing's high-touch approach, along with its industry expertise and SAP consulting capabilities in enterprise asset management, consumer industries, and human experience management, will be instrumental in advancing Wipro's position as a sought-after advisor for clients' most complex SAP transformations...As one of the leading strategic partners in the world for SAP, Rizing will become a critical extension of Wipro's SAP Cloud practice and Wipro FullStride Cloud Services. The combined offering will help clients surface unique business opportunities and new competitive advantages through SAP cloud implementations. It will also help Wipro expand its leadership in oil & gas, utilities, manufacturing, and consumer industries." Upon completion of the acquisition, Rizing will operate as Rizing, a Wipro company, under the leadership of Maiolo. Rizing is headquartered in Stamford, CT, and has more than 1300 employees in 16 countries across North America, Europe, Asia, and Australia. Rizing was previously owned by private equity firm One Equity Partners. Guggenheim Securities, LLC acted as exclusive financial advisor to Rizing for this transaction. The acquisition is subject to regulatory approvals and is expected to close before the end of the quarter ending June 30, 2022.

09:39 EDT One Equity Partners to sell Rizing to Wipro, terms not disclosed - One Equity Partners announced that it has entered into a definitive agreement to sell Rizing, a SAP-focused provider of IT systems integration and implementation services, to Wipro. The company said, "Headquartered in Stamford, Conn., Rizing specializes in value-added products and IT business process solutions operating within the SAP ecosystem, including enterprise asset management, human capital management, and related IT solutions for clients in consumer industries. Rizing serves leading global customers with more than 1,250 employees around the world working from locations in the U.S., Canada, the Netherlands, Australia, the United Arab Emirates, Singapore and Malaysia."

09:29 EDT Citi implementing U.S. sanctions against Russia, says CEO Fraser

09:27 EDT Citi still sees 3-5 year ROTCE 11%-12% - Comments taken from Citi's annual shareholder meeting.

09:27 EDT Live Current Media completes merger with Kast - Live Current Media announces that it has completed its merger with Evasyst of San Diego in an all share transaction. Evasyst owns and operates the Kast online, social, watch party platform. Kast is an online, social, video streaming and watch party platform and community where friends gather to watch videos, play games, and be together. According to Grandview Research, the global video streaming market is expected to grow at a compound annual growth rate of 21.3% between 2022 and 2030. The Kast platform empowers individuals to live-share synchronized video, engage and collaborate within the community and build relationships with like-minded people. Pursuant to the merger plan, the Company has issued 125 million common shares to the existing shareholders of Evasyst to purchase 100% of the outstanding shares. On closing, David Jeffs resigned as CEO and Mark Ollila, CEO of Evasyst, was appointed CEO and Chairman of the board of Live Current. Mr. Ollila has over twenty years of experience in the games and media technology industry previously with senior roles at Nokia and Microsoft, including leading Nokia First Party Games Publishing. In addition to Mr. Ollila, the new board of directors is comprised of the following members; Heidi Steiger, Leslie S. Klinger, Justin Weissberg, Annamaria Rapakko and David Jeffs who will maintain his previously held position on the board. The new board brings a wealth of experience in the legal, financial and gaming sectors and corporate governance to the Company and will be relied on heavily moving forward. John DaCosta and Amir Vahabzadeh have resigned from the board effective April 22, 2022 and the Company thanks them for their contributions over the past 5 years. Joining Mr. Ollila on the management team are Steve Smith assuming the role of CFO and David Jeffs continuing on in his previously held roles as President and Secretary.

09:25 EDT Mace Security partners with Cornwell Quality Tools - Mace Security is pleased to announce the Company has partnered with Cornwell Quality Tools to offer its personal safety products through more than 750 mobile tool franchisees across the United States. Cornwell Quality Tools has been manufacturing and distributing tools to the automotive and aviation industries for more than 100 years. Its extensive coverage across the country matches well with Mace's strategy of providing safety products across all U.S. markets. The partnership expands the Company's presence in the automotive and heavy-duty truck technician market of approximately 630,000 in the U.S. The majority of the technician market is comprised of males that are more likely than the average citizen to be interested in personal safety and self-defense.

09:23 EDT Jamf Holding showcases new offerings for managing Apple-first enterprise - Jamf holds a special Jamf Event to showcase a number of new offerings it has developed to help organizations deliver an enterprise-secure, consumer-simple environment that protects personal privacy. Key announcements include:Jamf Protect: a comprehensive endpoint and network security platform built for Apple: Jamf announces a new set of endpoint protection technologies for macOS, with the goal of providing all of the tools an organization needs, in one platform, to maintain good device security hygiene, detect attacks, and stop malware from compromising endpoints, while also preventing incoming threats before they put users or devices at risk. Enhancements to Jamf Protect include: Network threat prevention: The most successful strategy for dealing with threats to macOS endpoints is to prevent them from reaching devices in the first place. To address the need for threat prevention on macOS, Jamf announces that it is extending its macOS endpoint protection feature set to now include threat prevention capabilities that add network-based indicators of compromise into the solution. Powerful analytics: Jamf's endpoint protection provides comprehensive logging for both endpoint and network security events, allowing InfoSec teams to isolate and remediate detected threats, investigate incidents using data both on the device and from the network, and experience visibility into their environments. Removable storage: Jamf announces new removable storage controls to ensure sensitive business data is only written to encrypted USB mass media drives, which protects against physical loss and unauthorized data access. Jamf Trust: End user app: Jamf also announces the launch of Jamf Trust, an intuitive app for employees that powers workflows related to Jamf's security products, including Jamf Threat Defense, Jamf Safe Internet, Jamf Data Policy, and Jamf Private Access. Jamf Trust will give users access to powerful security capabilities without impacting performance or productivity. Jamf Trust will launch across iOS, iPadOS, macOS, Android and Windows this May. Jamf Safe Internet: Powerful and safe learning with Apple: Jamf Safe Internet combines content filtering and network threat prevention features that block unsafe content and malicious attacks so students can learn safely from anywhere. This includes protecting against malware and phishing attacks. Jamf Safe Internet is driven from a vast content-filtering database, and includes lightweight technology to filter results without invading student privacy and without sacrificing the learning experience that Apple devices provide. Jamf Safe Internet will be available for macOS and iOS this summer. Jamf Fundamentals: The intersection of management and security: The Jamf Fundamentals plan combines Jamf's market-leading device management technology with new capabilities for protecting, connecting, and empowering small to midsized businesses with Apple. Through malware prevention, password sync, self-service functionality for Mac, and the ability to deploy apps, custom profiles, macOS packages and more, businesses have an intuitive but powerful way to manage and secure their Apple fleet. Jamf Fundamentals is available today. BYOD: Powering and protecting employees wherever they work from: Jamf demonstrated a new bring-your-own-device workflow that preserves personal privacy by preventing IT from having too much control over an employee's device, yet addresses IT concerns by allowing them to adequately manage and secure the device while it's accessing company resources. Leveraging Apple's account-driven user enrollment workflow, Jamf's BYOD offering allows employees to easily enroll their personal devices and gain secure access to the apps they need to be productive, without authorizing excessive management. By separating corporate data from personal data, work apps and information are safe and secure while the employee retains personal and private use of their device. Jamf's BYOD offering is available now. App Installers: Revolutionizing application lifecycle management: The next evolution in Application Lifecycle Management is here with the launch of App Installers, part of the Jamf App Catalog, a simplified way for IT to deploy and update Mac applications. This new, powerful workflow provides a streamlined install and update mechanism for apps, mirroring the simplicity of the Mac App Store and removing the tedious tasks of sourcing, deploying and maintaining non-Mac App Store titles. App Installers, part of Jamf's robust application lifecycle management solution, now delivers the volume of supported apps that organizations require, matching the velocity with which these updates are made available, and with the validation needed for organizations to trust the quality and security of the update. App Installers is available today.

09:21 EDT Petros Pharmaceuticals enters into SPA with Massachusetts General Hospital - Petros Pharmaceuticals announces it has entered into a Sponsored Research Agreement, SRA, and an Option Agreement with the Wellman Center of Massachusetts General Hospital, an affiliate of Harvard Medical School. Under the agreement, researchers will evaluate incorporating the use of a tissue-specific oxygenation sensor with the goal of monitoring and understanding the success of Erectile Device Therapy. Accompanying the Sponsored Research Agreement, Petros will enter into an Agreement for an option to negotiate an exclusive license of the tissue-specific oxygenation sensor within specific human tissues. The Company plans to apply the technology to potentially enhance its existing erectile device therapy. "We believe what Mass General has developed is a truly landmark achievement in immediate and highly-targeted bio-sensor feedback technology," said Fady Boctor, Petros Pharmaceuticals' President and Chief Commercial Officer. "This relationship with the Wellman Center at Mass General has the potential to empower the male patient with innovative technology to enhance at-home therapy in the area of erectile dysfunction by demonstrating the effectiveness of external devices in an additional non-invasive context."

09:20 EDT Intapp, KPMG form strategic alliance to accelerate digital transformation - Intapp announced that it has entered a strategic alliance with KPMG AG. Intapp and KPMG will enable private capital, investment banking, legal, accounting, and consulting firms as well as corporate legal department clients to harness the full power of the cloud through purpose-built solutions and services. This strategic alliance will facilitate firmwide connectivity, allowing professionals to provide more effective and insightful services using cloud technology that unlocks the full value of data, delivers context-aware intelligence, and fosters greater operational efficiencies. The alliance will deliver three key benefits to clients: "Trusted cloud transformation... Intelligent solutions for modern professionals... Continuous innovation." "Working jointly with KPMG - a proven leader in cloud and digital transformation - Intapp can further serve the accelerating demand for cloud adoption within the professional and financial services industry," said John Hall, CEO of Intapp. "Together we'll provide our expanding client base with a rich ecosystem of industry-specific experts and purpose-built cloud solutions to further support holistic digital transformation at scale."

09:16 EDT DIAGNOS extends contract with Novo Nordisk - Diagnos is pleased to announce the extension of its contract for the follow-up of Diabetic patients under treatment with drugs included in its therapeutic portfolio. Novo Nordisk's therapeutic portfolio offers positive benefits by reducing the risk of developing retinopathy and of suffering from major cardiovascular events such as heart attack, stroke, or even death in adults with type 2 diabetes mellitus with known heart disease.

09:15 EDT ENGlobal subsidiary receives $2.5M Defense Logistics Agency contract order - ENG announced that its wholly owned subsidiary, ENGlobal Government Services, has been awarded a new contract order by the Defense Logistics Agency, or DLA, a sub-tier of the Department of Defense, to upgrade the Automated Fuel Handling Equipment, or AFHE, at two undisclosed major U.S. military bases. The contract is expected to start in May and last for approximately 15 months. The contract, currently estimated at over $2.5M, is to update Automated Fuel Handling Equipment and Supervisory Control and Data Acquisition systems which are comprised of computers, networked data communications, and graphical user interfaces. The AFHE system provides the end users with assured real-time data acquisition and automated inventory management thus allowing for more efficient operations.

09:14 EDT Editas Medicine receives FDA Rare Pediatric Disease designation for EDIT-301 - Editas Medicine announced that the U.S. Food and Drug Administration, FDA, granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia. The FDA previously granted Rare Pediatric Disease designation to EDIT-301 for the treatment of sickle cell disease. "Beta thalassemia is a devastating disease that leads to severe anemia, organ failure, and premature death. Receiving Rare Pediatric Disease designation for EDIT-301 for beta thalassemia highlights the dire need for new treatment options," said James C. Mullen, Chairman, President, and Chief Executive Officer, Editas Medicine. "EDIT-301 is a potentially transformative medicine for patients living with beta thalassemia, and we look forward to dosing the first patient in our clinical trial this year." EDIT-301 is being investigated in a clinical study in patients with severe SCD. Editas expects to initiate a Phase 1/2 study of EDIT-301 in patients with transfusion-dependent beta thalassemia in 2022.

09:12 EDT GeoVax Labs announces issuance of malaria vaccine patent - GeoVax Labs announced that the U.S. Patent and Trademark Office has issued Patent No. 11,311,612 to GeoVax, pursuant to the Company's patent application No. 16/648,693 titled "Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria." In general, the claims granted in the patent cover GeoVax's modified vaccinia Ankara, MVA, vector expressing certain antigens from the malaria parasite. David Dodd, GeoVax President and CEO, commented, "We remain strongly committed to advancing innovation towards improving public health worldwide and this patent reflects a potentially significant advance relative to malaria prevention. Our development priorities continue to be our COVID-19 vaccine, currently in Phase 2 clinical trials, and our cancer immunotherapy program, with Gedeptin as our lead product in a Phase 1/2 clinical trial for Head and Neck cancer. However, developing vaccines against global public health threats such as malaria, is also part of our longer-term focus. Collaborations with government and academic institutions, such as the NIH, USAID, and the Burnet Institute, will continue to be components of our efforts to design, produce and test novel vaccines against malaria. Our goals include developing such vaccines that are affordable, highly effective, safe, and can be distributed and administrated across various regions of the world in a simple manner."

09:10 EDT Charles & Colvard announces agreement with Cooksongold - Charles & Colvard announced a strategic distribution agreement with Cooksongold, a division of Heimerle + Meule Group in Europe. "We are pleased to become an authorised distributor for Charles & Colvard's Forever One and Moissanite by Charles & Colvard brands; these are a fantastic addition to Cooksongold's range!" said Martin Bach, Managing Director of Cooksongold.

09:09 EDT Worksport unveils Terravis Energy green hydrogen energy systems - Worksport unveils brand new green hydrogen-powered systems from its research and development subsidiary, Terravis Energy. The Terravis Energy website provides information on everything being released, answering those questions about capabilities of its versatile, fast charging Non-Parasitic Electric Vehicle systems, the Terravis Energy Microgrid, and the Terravis Energy Nanogrid, as well as featuring some surprise innovations. "Going live for the very first time is a very exciting event. The Terravis Energy website represents the work of many talented and dedicated people who have spent countless hours making this occasion a memorable one. The single most important purpose for the Terravis Energy website is communication. As such, it will be continually updated with new information as it becomes material. For an especially energizing, high-level experience, I would recommend taking a few minutes to enjoy our video. Clean energy is the future, and the future is now," said Lorenzo Rossi, CEO Terravis Energy.

09:09 EDT Sirius XM to cover the 2022 NFL Draft - SiriusXM will provide listeners nationwide with comprehensive coverage of the 2022 NFL Draft, with live announcements of every selection from every round and in-depth analysis on the SiriusXM NFL Radio channel, as well as additional NFL Draft-focused programming on other SiriusXM channels. Immediately following the conclusion of SiriusXM NFL Radio's Draft broadcast each day, the channel will have live call-in shows where fans can share their reactions and discuss their favorite team's picks.

09:07 EDT Lionsgate and the Roku Channel announce theatrical output deal - Lionsgate and THE ROKU CHANNEL, the home of free and premium entertainment on Roku, the TV Streaming Platform, have closed a multiyear theatrical output deal for theatrically released Lionsgate films beginning with the studio's 2022 theatrical releases, the companies announced today. Under the terms of the agreement, THE ROKU CHANNEL will receive two separate windows for each film, the first of which provides exclusive rights to Lionsgate's film slate immediately following its first window on STARZ. The agreement will include properties such as the blockbuster JOHN WICK action franchise starring Keanu Reeves, EXPENDABLES 4, featuring an A-list cast of action stars, and BORDERLANDS, directed by Eli Roth and starring Academy Award winner Cate Blanchett, Kevin Hart, Jamie Lee Curtis and Jack Black.

09:06 EDT EnWave reports successful injunction application against former CEO - EnWave Corporation received the written reasoning from the B.C. Supreme Court granting an injunction application against its former CEO, Timothy Durance, his companies and affiliates. EnWave continues to pursue its civil claims in the B.C. Supreme Court against several former EnWave employees and other parties, including Timothy Durance. On July 30, 2021, EnWave filed an injunction application seeking orders restraining Mr. Durance, his companies and affiliates from selling or supplying vacuum microwave dryers pending trial. On August 20, 2021, the court granted an order prohibiting Mr. Durance and his companies, and anyone acting in conjunction with them, from selling, attempting to sell, supplying, delivering or installing vacuum microwave dryers pending a more complete hearing of EnWave's injunction application. EnWave's injunction application was heard in the B.C. Supreme Court from January 17 to 20, 2022. On April 25, 2022, the court issued reasons for judgment ordering that the injunction against Mr. Durance, his companies and affiliates remain in place until the trial of EnWave's action. The reasons for judgment will be publicly available through the B.C. court website later today. A trial is scheduled for September 2023.

09:05 EDT Ocuphire Pharma to present at ARVO 2022 meeting, MODLive! 2022 - Ocuphire Pharma announced four poster presentations by key thought leaders Drs Boyer, Devries, Katz, and Pepose on APX3330 and Nyxol at the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Denver, CO from May 1-4, 2022. In addition, Ocuphire represented by Bindu Manne, Head of Market Development and Commercialization, will be featured in a podium discussion at the MODLive! Optometry Meeting in Nashville, TN on May 5, 2022. ARVO Annual Meeting - May 1-4, 2022: Session: New drugs, mechanisms of action and ocular toxicology: Title: The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial. Dr. Boyer will present masked safety data from the ongoing ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The results show a favorable ophthalmic and systemic safety and tolerability profile, consistent with 11 prior safety trials of APX3330 in non-ophthalmic indications. The company expects to report top-line results from the ZETA-1 trial in second half of 2022. Session:Aqueous humor dynamics, IOP, corneal disease, cytokines and growth factors. Title: Phentolamine Ophthalmic Solution Reverses Pharmacologically Induced Mydriasis in Healthy Subjects: Subgroup Analyses in the Pivotal Phase 3 MIRA-2 Randomized Controlled Trial: Ocuphire will present pre-specified subgroup analyses from the MIRA-2 Phase 3 trial of Nyxol to reverse pharmacologically-induced mydriasis. Analyses were stratified by drops, iris color, and mydriatic agent. Results showed that Nyxol rapidly reversed mydriasis by significantly returning pupil diameter to normal in 60 to 90 minutes using both one and two drops across mydriatic agents and iris colors. MIRA-2 and the recently completed MIRA-3 represent two well-controlled, confirmatory Phase 3 clinical trials evaluating Nyxol in RM to support an NDA submission with the FDA planned in late 2022. Session: IOLs and Presbyopia. Title:VEGA-1: Phentolamine Ophthalmic Solution as a Single Agent Improves Distance-Corrected Near Visual Acuity in Patients with Presbyopia" Ocuphire will present efficacy data from pre-specified endpoints in the VEGA-1 Phase 2 trial of Nyxol in presbyopia. Results demonstrated that Nyxol as a single agent provided 12 to 18 hour durability and statistically significant improvement in distance-corrected near visual acuity. In addition, results also showed a favorable safety and tolerability profile, particularly notable being the absence of headaches. VEGA-1 supports the advancement to pivotal Phase 3 trials planned for mid-2022 evaluating the efficacy of Nyxol alone and in combination with low dose pilocarpine for presbyopia. Session: IOLs and Presbyopia; Title: The Efficacy of Phentolamine Ophthalmic Solution and Low-Dose Pilocarpine to Improve Distance-Corrected Intermediate Visual Acuity in Patients with Presbyopia: Dr. Pepose will present for the first time to the scientific community efficacy data from the VEGA-1 Phase 2 trial evaluating Nyxol in combination with low-dose pilocarpine to improve distance-corrected intermediate visual acuity (DCIVA) in patients with presbyopia. The results demonstrated that Nyxol and LDP combination had statistically significant improvement in DCIVA at 1 hour with durable results through 6 hours.

09:04 EDT Harvard Bioscience introduces new feature to its Buxco Inhalation System - Harvard Bioscience has introduced SmartStudy, a technology feature to its Buxco Inhalation System aimed at supporting more precise results, cost savings, and improved productivity for preclinical researchers. Product demonstrations were conducted in-booth during the recent Society of Toxicology annual meeting in San Diego and will be available again May 15-17 during the American Thoracic Society conference in San Francisco. SmartStudy permits researchers running small animal aerosol inhalation and exposure studies to shut off delivery of the test article to individual subjects when they have received the desire dosage while other animals continue to receive dosing. This is an exclusive feature of the Buxco Inhalation System which reduces the margin of error by being able to stop the known delivery amount. "SmartStudy combined with Accumulated Inhaled Aerosol or AIA is a natural progression of technological advances leading to scientific practices and results," said Jim Green, President and CEO of Harvard Bioscience. "This new technology gives our customers more control over their studies and their study experience for more precise results and a savings in time, money and subjects."

09:02 EDT Carnival names Josh Weinstein as new CEO - Carnival "announced that effective August 1st, Arnold Donald, currently President and CEO, is being appointed Vice Chair and member of the Boards of Directors. Josh Weinstein, currently COO for the company, will assume the role of President and CEO of Carnival Corporation & plc. In his most recent assignment for the past two years as Carnival Corporation & plc's Chief Operations Officer, Weinstein oversaw all major operational functions including global maritime, global ports and destinations, global sourcing, global IT and global auditing."

08:57 EDT D.R. Horton: Rising rates will impact affordability 'at some point'

08:56 EDT Amarin partner HLS Therapeutics completes reimbursement negotiations with pCPA - Amarin Corporationannounced its partner HLS Therapeutics has completed negotiations with Canada's pan-Canadian Pharmaceutical Alliance for the terms and conditions under which VASCEPA would qualify for public market reimbursement in Canada. Following these negotiations, HLS has signed a Letter of Intent which allows HLS to work with all participating provincial jurisdictions to secure coverage from publicly funded drug plans across Canada, and for VASCEPA to potentially be added to their respective plans. In September 2017, Amarin and HLS Therapeutics entered into an exclusive commercialization agreement between the parties to register, commercialize and distribute VASCEPA capsules in Canada. Under the agreement, HLS is responsible for regulatory and commercialization activities and associated costs. Amarin is responsible for providing assistance towards local filings, supplying finished product and maintaining intellectual property. Prior to the study's completion, Amarin had also been responsible for continuing the development and funding of REDUCE-IT. Terms of the agreement include up-front and milestone payments to Amarin of up to US$65.0 million. These payments include a non-refundable upfront payment of US$5.0 million, which Amarin received when the agreement was reached, as well as development, regulatory and sale-based milestones totaling up to an additional US$60.0 million. The agreement also provides for HLS to pay Amarin tiered double digit royalties on net sales of VASCEPA in Canada. Amarin is obligated to supply finished product to HLS under negotiated supply terms. The agreement for supply and commercialization is for Canada only and includes all Canadian provinces.

08:54 EDT Ecolab to narrow presence in Russia - The company said, "In light of Russia's invasion of Ukraine and the sanctions against Russia by the United States and other countries, Ecolab has made the determination that it will limit its Russian business to operations that are essential to life, providing minimal support for its healthcare, pharma, food and beverage and certain water businesses. Ecolab may further narrow its presence in Russia depending on future developments. Ecolab's Russian operations represented approximately 1% of Ecolab's 2021 annual sales."

08:53 EDT D.R. Horton deliberately slowed sales in Q2

08:49 EDT KeyCorp announced elimination of non-sufficient fund fees and other measures - KeyBank announced the elimination of non-sufficient fund fees, a reduction in overdraft fees, and other steps to help clients manage their finances. Initially discussed at KeyCorp's Investor Day on March 1, additional details are being released today. These changes, expected to be offered beginning in late 2022, also include enhancements to products to make them even more convenient and flexible for clients. Currently, KeyBank offers the KeyBank Hassle-Free Account, a Bank On certified product with no overdraft, monthly maintenance service charges or minimum balance fees. Changes being announced and taking effect in late 2022 will apply to KeyBank's other checking and savings accounts and include: Elimination of non-sufficient fund fees; Introduction of a $20 de minimis threshold, where clients won't incur overdraft fees for negative balances below this level; Reduction of overdraft fee to $20 per occurrence; Institution of an overdraft fee cap of three per day; Provision of $0 Overdraft Protection for all linked accounts.

08:47 EDT Toll Brothers announces opening of Eloise at Grant Park - Toll Brothers announced the opening of the townhome collection at Eloise at Grant Park, a community of 12 townhome and 18 condominium home designs just minutes from Grant Park. "Our community offers modern floor plans designed for today's homebuyers within Atlanta's largest historic district," said Jonathan Carter, Toll Brothers Division President of the Atlanta Urban Division. "The exceptional design of each townhome and the outstanding location combine to provide a truly desirable urban lifestyle."

08:46 EDT Iteris awarded $3.7M smart mobility, contract from OCTA - Iteris announced that it has been awarded a $3.7M contract from the Orange County Transportation Authority OCTA for a regional smart mobility, safety and sustainability program, representing continued demand for Iteris' mobility consulting and mobility intelligence services in southern California, a key geographic market.

08:44 EDT Paltalk launches mobile backgammon game - Paltalk is pleased to announce the launch of its mobile backgammon game enabling Paltalk users to play with friends, other users or privately with real-time voice and video. Paltalk believes that providing additional interactive offerings and content on its platforms, such as mobile backgammon, will lead to increased user engagement. The Company believes that existing subscribers will introduce mobile games to potential new subscribers. Mobile backgammon was initially released on Android and is expected to become available on Desktop by the end of the second quarter of 2022.

08:43 EDT UPS says has suspended all operations in Ukraine, Belarus, Russia - Says "pleased" with Q1 results. Says all segments delivered operating profit growth in Q1. Says seeing "many positives" inside the business. Says "confident" in outlook and financial position. Comments taken from Q1 earnings conference call.

08:43 EDT Galecto completes enrollment in global Phase 2b GALACTIC-1 trial of GB0139 - Galecto announced it has completed enrollment of patients in its Phase 2b GALACTIC-1 trial of GB0139 for idiopathic pulmonary fibrosis, IPF. "We are very excited to complete enrollment in this Phase 2b trial in IPF and are encouraged by the support of the clinical investigators and patients participating in the trial. Limited treatment options for patients with IPF make it an area of significant unmet need and patients would benefit from innovative and disease-modifying treatment options that are safe and well-tolerated," said Dr. Hans Schambye, President and Chief Executive Officer of Galecto. "Once-daily inhaled GB0139 offers the potential to play an important role in filling this unmet need with its demonstrated ability to specifically target galectin-3, one of the key regulators in the disease. We look forward to topline data from this study in mid-2023." GALACTIC-1 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 2b study being conducted across approximately 100 centers globally. The primary endpoint of the trial is to assess the annual rate of decline in forced vital capacity.

08:42 EDT D.R. Horton sees Q3 home sales gross margin 'slightly better' than Q2

08:42 EDT D.R. Horton hasn't seen improvement in supply chain yet

08:41 EDT D.R. Horton 'well-positioned' for revenue growth of over 25% this year

08:40 EDT Vicinity Motor in distribution pact with Soderholm Sales & Leasing - Vicinity Motor announced that it has signed a non-exclusive distribution agreement with Soderholm Sales & Leasing, a full service bus dealer in Hawaii and the Pacific islands region, to offer the Company's Vicinity LightningTM, Vicinity Classic and VMC-Optimal vehicles, including an initial commitment for four demo and stock buses. Founded in 1989, Soderholm Sales & Leasing, Inc. is a woman- and multigenerational family-owned and operated company - acting as the only fully licensed, full-service bus dealer in Hawaii and the Pacific. The company's product mix includes new and used, small and mid-sized buses, full-sized motor coaches, school buses, vans, trams, and trolleys. Located on Oahu, SSL serves the State of Hawaii, and is the largest dedicated bus dealer in the U.S. South Pacific servicing 28 islands including Guam, Saipan and American Samoa.

08:40 EDT OLB Group announces receipt of $240M valuation from from independent firm - OLB Group announced that the company has received a $240M valuation from Corporate Valuation Advisors, an independent valuation and appraisal firm that provides valuation advisory services and fairness opinions to public and private companies. OLB engaged the firm to determine the company's fair market value and provide a comparison to similar companies in the industries where OLB does business. OLB received the valuation as of December 31, 2021, and since then has closed its acquisition of Crowd Ignition and expanded its cryptocurrency mining operation by securing 10,000 square feet of leased space in Bradford, Pennsylvania. The valuation noted that the company increased its value in the fourth quarter of 2021 as the result of the addition of new merchants and the formation of several new business ventures included in the year-end projections.

08:39 EDT D.R. Horton: New home demand 'very strong' - Comments taken from Q2 earnings conference call.

08:38 EDT Point Biopharma announces first patient dosed in EU in Phase 3 SPLASH trial - POINT Biopharma Global announced the first patient in the European Union, EU, has been dosed in the Phase 3 SPLASH trial. The SPLASH trial is investigating the use of 177Lu-PNT2002, a PSMA-targeted radioligand, in pre-chemotherapy metastatic castration-resistant prostate cancer, mCRPC, with entry criteria including a positive PSMA-PET scan with either 68Ga-PSMA-11 or 18F-DCFPyL. The SPLASH trial began randomization in North America in September 2021, and a total of 37 trial sites across North America and Europe are currently enrolling patients. Site activations in remaining jurisdictions continue to further accelerate trial recruitment. The Company continues to expect to report top line data from SPLASH mid-2023. "I'm pleased with our team's consistent execution of the SPLASH trial," said Dr. Joe McCann, CEO of POINT Biopharma. "In two years, we've gone from a pre-IND meeting with the FDA to dosing patients in multiple countries, and I'm proud of our team for realizing this achievement. We remain on track to complete recruitment by the end of this year, and to disclose efficacy and safety data from the 27-patient lead-in in the second half of 2022."

08:38 EDT Warner Bros. Discovery says CNN+ was a chunky investment - Says has no religion on one platform over another. Says focus is to invest in content and platforms. Says ultimate goal is to drive free cash flow. Says has 100M collective subscribers. Says not trying to win direct-to-consumer spending war. Says HBO Max is on a roll. Says Q1 operating profit and cash flow for Warner Media were below expectations. Says 2022 will be a messy year with moving pieces. Says on HBO Max there's huge amount of content that's not being used on subscription platform. Says combined company spends $5B per year on marketing. Says reiterates FY23 targets. Comments taken from Q1 earnings conference call.

08:36 EDT ABVC BioPharma announces Vitargus Phase II study investigator meeting - ABVC BioPharma announced that the principal investigators of the Phase II clinical study of Vitargus will hold a virtual meeting on April 27, 2022. The meeting will be attended by all principal investigators currently selected from the Australian and Thailand sites to help coordinate the study, entitled "A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of ABV-1701 Ocular Endotamponade." "We are proceeding steadily according to our Vitargus development plan," said Dr. Howard Doong, CEO of ABVC BioPharma. "The investigator meeting will facilitate a mutual understanding of the study's goals and set procedures to share experiences among the Principal Investigators. The Australian and Thai sites are expected to enroll approximately 40 patients in the study, which is a good starting point for our goal to enroll at least 175 patients in multiple countries by the end of 2023."

08:35 EDT Biomerica announces FDA submission for test to detect H. pylori bacteria - Biomerica announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, FDA, for hp+detect, a new product that detects the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population. Under the current FDA 510(k) Premarket Notification Process, the FDA's goal is to provide a decision within 90 days to the submitting company, unless further information is requested. Biomerica is also preparing to submit a CE Mark filing, which will enable the product to be sold in most EU countries and other regions around the world. Biomerica's Chairman and Chief Executive Officer Zack Irani stated, "This FDA submission is a milestone in our commitment to bringing a diagnostic solution for the over 115 million people suffering from H. pylori infection across the U.S. today. We're particularly excited about this product as it has shown to be highly accurate as compared to other products in the market. We've also created an efficient, low-cost manufacturing process that should enable high gross margins on this product."

08:35 EDT Missfresh triples stock volume in Beijing after increase in COVID-19 cases - After some of COVID cases in Beijing and mass COVID-19 testing in most of the city, residents snapped up food and other suppliers with the fear of rising number of cases. Missfresh has tripled its stock volume to meet consumer demand during this time with more than 200 tons of "essential for livelihood" commodities such as meat, eggs, vegetables, and fruits, the Missfresh customers are able to access to fresh goods. In addition, the supplies of other non-perishable foods including oil, frozen foods and meats have also been expanded and stocked. For more than 20 stores in key areas, Missfresh is carrying out a second round of replenishment in the afternoon and will continue to increase shipment according to the consumer demand.

08:34 EDT Vivos Therapeutics opens third U.S. multidisciplinary sleep apnea clinic - Vivos Therapeutics announced that Vivos' medical integration division will open its third U.S. multidisciplinary sleep apnea clinic in May 2022 in Toluca Lake, Calif. The new facility will join existing Pneusomnia Centers in Del Mar and Modesto, Calif. The Center will be a clinician-owned, Medicare-approved clinic. It will provide a comprehensive array of services that include The Vivos Method treatment for both adults and children, mandibular advancement devices, laser treatment, oral myofunctional therapy, home sleep testing and positive airway pressure services. The Center will be led by Dr. Jonathan Greenburg, DDS, a nationally renowned expert in dental sleep medicine and faculty member at The Vivos Institute in Denver, Colo., and Dr. Michael Marsh, MD, an American Board of Internal Medicine diplomate who has practiced internal medicine for over 25 years.

08:33 EDT Entasis Therapeutics presents five poster presentations at ECCMID - Entasis Therapeutics announced five poster presentations highlighting additional SUL-DUR and ATTACK details and results were presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, annual conference, held April 23-26, 2022 in Lisbon, Portugal. "Characterization of Co-Infecting Gram-negative pathogens isolated in addition to Acinetobacter baumannii-calcoaceticus complex at baseline from patients enrolled in the ATTACK Phase 3 trial" examined the susceptibilities of co-infecting Gram-negative pathogens from the ATTACK trial to SUL-DUR plus imipenem. 33% of m-MITT ATTACK patients were co-infected with at least one other Gram-negative pathogen. Notably, only 45% of these isolates were susceptible to imipenem alone while 73% were imipenem-susceptible in the presence of SUL-DUR. "Sulbactam-durlobactam in vitro dose response studies with and without imipenem or meropenem against carbapenemase-producing Acinetobacter baumannii utilizing the hollow-fiber infection model" showed that, at clinically relevant exposures, SUL-DUR alone exhibited robust killing activity against a carbapenem resistant Acinetobacter isolate with a SUL-DUR MIC below the preliminary breakpoint. "Safety profile of sulbactam-durlobactam versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex infections from the global, randomized, active-controlled phase 3 trial" reported that 12.1% of ATTACK patients receiving SUL-DUR experienced drug-related Treatment Emergent Adverse Events compared to 30.2% in the colistin group and that nephrotoxicity occurred significantly less often with SUL-DUR: 13.2% vs. 37.6%. "Efficacy and safety of sulbactam-durlobactam therapy in patients with Acinetobacter baumannii-calcoaceticus complex infections in the open label Part B of the ATTACK phase 3 trial" showed a comparable 28-day ACM in Part B of ATTACK to that of Part A, despite 57% of Part B patients infected with colistin-resistant Acinetobacter. "In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus Complex isolates from a five-year surveillance Program" highlighted SUL-DUR's potent in vitro activity against ABC isolates from diverse infections and geographical locations with an MIC90 value of 2 mg/L and 98.2% inhibited at less than or equal to4 mg/L.

08:33 EDT Coversus StepStone Private Markets exceeds $500M in AUM - Conversus announced that its inaugural fund, Conversus StepStone Private Markets, has surpassed $500 million of assets under management. CPRIM, which offers accredited investors diversified, global exposure to the major private market asset classes-private equity, real assets, including infrastructure and real estate, and private debt-in a single investment, was launched on October 1, 2020, achieving this AUM milestone within 18 months. Conversus acts as adviser to CPRIM and is a wholly owned business of StepStone Group, which acts as sub-adviser. CPRIM has generated net asset growth per share of over 70.5% through March 31, 2022, with NAV increases in 16 of its 18 months since inception. These gains were driven primarily by realizations and strong performance in the fund's portfolio of over 750 companies that are broadly diversified on all key metrics. CPRIM continues to expand its portfolio each month with new private equity and real asset investments sourced by StepStone's global platform of over 750 professionals with offices in 23 cities across 14 countries. Conversus also announced two key new hires within its global distribution team to support the growth-Brett Schlemovitz as Managing Director of Private Wealth Solutions and Celine El Debs as Managing Director of Europe, Middle East and Asia. Schlemovitz joins Conversus from CNL Financial Group where he oversaw the firm's Private Equity platform and was Chief Operating Officer of Strategic Capital. He is based in New York. El Debs joins Conversus from Quintet Private Bank where she led the offering and distribution of alternative investments, including private markets. She is based in Zurich, Switzerland.

08:30 EDT Codex DNA completes proof-of-concept demonstrations for DNA data storage - Codex DNA announced the completion of proof-of-concept demonstrations showing that its technology can be used effectively for encoding digital data in DNA sequences, and that the information that was stored could be retrieved accurately afterward. This validation is an important step in the company's efforts to develop next-generation tools and applications for DNA data storage. DNA can be used to store digital data by converting the binary code of 0s and 1s in data files into the A, C, G, and T building blocks of nucleic acids. The storage capacity of a DNA molecule is significantly higher than that of standard data storage technology, with the potential for encoding more than 200 petabytes of data per gram of DNA. It also lasts longer; DNA has been shown to remain intact for more than 1 million years. As a result, this method of storing and retrieving digital data using DNA can revolutionize the way data is stored. In this study, Codex DNA researchers used the company's proprietary software algorithm to encode data files into DNA sequence, optimized the synthesis of that DNA sequence, and then successfully demonstrated the retrieval and decoding of the DNA data with sequencing, completing the end-to-end workflow. The team used this approach for an audio file - a brief snippet from "Hey Jude" by The Beatles - and an image file of the company logo. The work leverages a Codex DNA patent for encoding data into nucleic acids. Separately, with these same algorithms and approach, Codex DNA researchers used the BioXp 3250 system to both store and retrieve an image file representing the Codex DNA logo. The company logo was divided into 18 DNA sequences that were individually synthesized and error-corrected on the BioXp system. The DNA data fragments were further processed on the same BioXp system to generate DNA sequencer-ready materials. Once sequenced, the file was found to match the original data file exactly, thus demonstrating for the first time an end-to-end automated solution for DNA data storage and retrieval. The Codex DNA R&D team continues to enhance its DNA data storage capabilities within the BioXp system workflows, including the unique algorithm to ensure that data is encoded only in the most stable and easily sequenced regions of DNA and the Gibson Assembly method for file indexing and compression. In addition, the company is applying its recently announced SOLA enzymatic DNA synthesis reagent solution to write DNA rapidly, efficiently, and with high accuracy for data storage applications.

08:27 EDT Amdocs selected by Vodafone to further modernize inventory portfolio - Amdocs (DOX) announced that it has been selected by Vodafone (VOD) to further harmonize and modernize its inventory portfolio in Germany, Romania, Czech Republic and Albania, for its mobile, fixed and cable offerings. This is the first time Amdocs has signed an agreement with Vodafone Albania. "Advanced inventory capabilities will provide Vodafone a powerful data foundation as it continues to automate its network and service operations for a network spanning multiple countries and new network technologies such as 5G," the company said. Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs, said: "Service providers worldwide are embarking on an accelerated journey to transform their businesses. Vodafone is a world leader in our industry, and we are proud to have been chosen to support its vision for the cross-regional harmonization of its inventory systems, and we look forward to continue working closely together."

08:25 EDT Nauticus Robotics to launch Nauticus Fleet - Nauticus Robotics announced the initial production run of Nauticus Fleet, a robotic navy of 20 Hydronaut - Aquanaut pairs. These tandem pairs will be deployed in multiple offshore industries serving applications ranging from subsea maintenance and intervention to data collection activities. These first sets of robots will be delivered in Q4 2022, with the remainder being fulfilled by the end of 2024. "Nauticus Fleet represents the most promising operational and technological step changes in this industry," said Nicolaus Radford, CEO of Nauticus. "We are on a mission to create a future where more autonomous and intelligent robots are used to significantly reduce environmental impact and human exposure to hazards, while at the same time improving the bottom line for our clients." On December 16, 2021, Nauticus and CleanTech Acquisition, a special purpose acquisition corporation, entered into a definitive business combination agreement that would result in Nauticus becoming a public company.

08:25 EDT GE sees supply chain, inflation pressure in Healthcare persisting through 2022

08:24 EDT General Electric 'on track' to reach over $7B of free cash flow in 2023

08:24 EDT Freshworks CRM for e-commerce available in Shopify App Store - Freshworks announced Freshworks CRM for e-commerce is now available in the Shopify App Store. The solution integrates directly with Shopify to provide its millions of merchants with a unified CRM that enables live conversational support, marketing and sales where and when consumers want to buy online. Freshworks CRM for Shopify is a unified marketing, support, and sales solution purpose-built for Shopify storefront owners. Merchants can create more engaging customer experiences by segmenting and marketing to their customers based on custom Shopify events like cart abandonment and first-time visitors; and by automating and personalizing messages across email, live-chat, WhatsApp, and SMS using pre-built Shopify Playbooks.

08:22 EDT DZS announces ongoing partnership with Northeast Nebraska Telephone Company - DZS announced its ongoing partnership with Northeast Nebraska Telephone Company to upgrade its entire first-generation, fiber-to-the-home triple play network with a world-class, next generation gigabit services network featuring both Active Ethernet and GPON technologies. The DZS Velocity portfolio of Broadband Connectivity systems was selected to deliver both Active Ethernet and GPON technologies and prepare NNTC's network, which serves 30 communities across 24 counties in rural northeast Nebraska, for a hyper-connected, multi-gigabit future.

08:21 EDT Amedisys promotes Muscato as Chief Strategy Officer - Amedisys announces the promotion of Nick Muscato to Chief Strategy Officer, effective immediately. Muscato was previously Senior Vice President of Finance for the company.

08:21 EDT Six Flags postpones Q1 earnings release until May 12 - Six Flags announced that it will postpone the release of its first quarter 2022 financial results previously scheduled for Monday, May 2 to before the market opens on Thursday, May 12. The change is due to unanticipated delays in completing the quarter-end closing process as a result of the implementation of a new enterprise resource planning system in the beginning of FY22.

08:19 EDT Athira Pharma files presentation on upcoming Annual Meeting of Shareholders - Athira Pharma announced that it has filed a new investor presentation with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Shareholders. Highlights of the presentation include: "Athira is successfully executing its strategic priorities and is well positioned as it enters its next pivotal chapter... Athira has a strong management team led by CEO Mark Litton, Ph.D., M.B.A.... Athira has the right board to oversee the company and a proven record of board development... Kayne's campaign is misguided and not in the best interests of all shareholders Kayne has rebuffed multiple attempts by Athira's board to constructively engage, and instead has advanced a costly, unnecessary proxy contest. Kayne has pushed an agenda to appoint himself to the board, terminate Dr. Litton as CEO and have Athira resume a relationship with the company's former CEO, Leen Kawas, PhD. Kayne has not publicly articulated any business strategy that differs from Athira's existing strategy," the company said.

08:18 EDT Optinose appoints R. John Fletcher to board of directors - Optinose announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. John founded Fletcher Spaght Inc. in 1983. He remains active with Fletcher Spaght, advising both the consulting practice and venture capital activities, with analytical insights and creative solutions derived from his years of experience with clients, portfolio companies and the investment community.

08:16 EDT VBL Therapeutics receives FDA Fast Track designation for ofra-vec - VBL Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for ofra-vec in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer. "We are pleased to receive FDA Fast Track designation for ofra-vec in platinum-resistant ovarian cancer. The Fast Track designation can facilitate the process towards potential registration and, importantly, may help expedite the time to market for ofra-vec, if approved," said Prof. Dror Harats, M.D., chief executive officer of VBL Therapeutics. "The readout of the progression free survival primary endpoint in the OVAL trial will be an important milestone for VBL in the second half of this year. We believe that, if positive, this will support a Biologics License Application submission to the FDA."

08:15 EDT Abiomed announces first patient implanted with Impella BTR - Abiomed announced the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery, or BTR, as part of the heart pump's FDA Early Feasibility Study, or EFS. The first implant was done at Northwestern Medicine Bluhm Cardiovascular Institute.

08:14 EDT Phathom Pharmaceuticals appoints Karbe to board of directors - Phathom Pharmaceuticals (PHAT) announced the appointment of Frank Karbe to its Board of Directors. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences (MYOV) brings over twenty-five years of financial and life-sciences expertise to Phathom.

08:12 EDT 89bio to host KOL webinar on severe hypertriglyceridemia - 89bio announced that it will host a key opinion leader webinar on severe hypertriglyceridemia on Wednesday, May 4, 2022 at 11:00 a.m. PT/ 2:00 p.m. ET. The webinar will feature presentations from KOLs Harold Bays, MD, President, Louisville Metabolic and Atherosclerosis Research Center, Inc., and Deepak L. Bhatt, MD, MPH, Brigham and Women's Health and Harvard Medical School. Dr. Bays will discuss the current disease state, treatment landscape, and unmet medical need for patients with severe hypertriglyceridemia. Dr. Bhatt will then discuss 89bio's ENTRIGUE Phase 2 clinical trial of pegozafermin in SHTG patients, prior data, the therapeutic rationale for developing pegozafermin in this setting, its unique mechanism of action and the potential to offer a compelling treatment option. Following Dr. Bays' and Dr. Bhatt's presentations, the 89bio leadership team will discuss the clinical/regulatory development path, and potential market opportunity for pegozafermin in SHTG.

08:11 EDT electroCore completes sale of New Jersey tax benefits - electroCore announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer program for fiscal year 2021. As a result, the Company has received approximately $445,000 in non-dilutive cash from the sale of these net operating loss, NOL, tax benefits. "We are pleased to have received $445,000 from the New Jersey NOL program," commented Brian Posner, Chief Financial Officer of electroCore. "This is the third consecutive year that we have benefited from this program which provides us non-dilutive funding that will be beneficial to us as we continue to invest in our sales channels and marketing initiatives to expand consumer awareness of gammaCore."

08:08 EDT United Airlines kicks off largest transatlantic expansion in company's history - United has kicked off the launch of its largest transatlantic expansion in its history, in anticipation of a strong recovery in European summer travel. In total, United will launch or resume 30 Transatlantic flights from mid-April through early June. This includes adding new nonstop flights to five distinctive leisure destinations no other North American airline serves including Amman, Jordan; Bergen, Norway; Azores, Portugal; Palma de Mallorca, Spain and Tenerife in the Spanish Canary Islands. The airline is also launching five new nonstop flights to some of Europe's most popular business and tourist hubs including London, Milan, Zurich, Munich and Nice. United is also resuming fourteen Atlantic routes the airline has historically served and adding frequencies in six others. United's transatlantic route network will be more than 25% larger than it was in 2019. With this expansion, United will serve more transatlantic destinations than every other U.S. carrier combined and will be the largest airline across the Atlantic for the first time in history.

08:06 EDT Laird Superfood launches Bright Cups pods - Laird Superfood announced the launch of Bright Cups, a commercially compostable single-serve coffee pod made with plant-based materials. Using its Focus Mushroom Coffee blended with functional mushroom extracts and botanical adaptogens, this is the first single-serve pod from Laird Superfood.

08:05 EDT Clear Secure launches expedited lanes at San Diego International Airport - As airports across the country experience a surge in passengers, Clear announced the launch of its expedited lanes in Terminal 2 at San Diego International Airport. SAN is Clear's eighth airport in California and 43rd nationally. Clear already serves all 10 of the airport's top 10 domestic destinations, and the company's entry into SAN will create approximately 27 new jobs and an overall economic impact of upwards of $2.4M for the region.

08:03 EDT General Electric CEO: Macro environment 'challenging'

08:02 EDT General Electric operations in Russia have been suspended, CEO says

07:56 EDT Freshworks launches Freshworks CRM for e-commerce - Freshworks launched Freshworks CRM for e-commerce, a customer relationship management solution with a unified customer record across conversational marketing, sales and customer support. Built for direct-to-consumer brands and digital retailers, the CRM solution empowers employees to engage their buyers directly through modern messaging channels, providing them with more personalized and delightful experiences. Freshworks CRM for e-commerce is now available directly from Freshworks and also on the Shopify App Store.

07:54 EDT PepsiCo: North American convenient foods, beverage business 'resilient' - PepsiCo expects its North American convenient foods and beverage businesses to remain resilient with some variability within channel mix dynamics as consumers adapt to ongoing inflationary pressures. Expects most International markets to perform well despite greater geopolitical and economic volatility and uncertainty, currency devaluations and COVID-related disruptions in certain regions.

07:47 EDT Vermilion announces ISS, Glass Lewis recommend shareholders vote for resolutions - Vermilion Energy announced that independent proxy advisory firms, Institutional Shareholder Services, or ISS, and Glass Lewis & Co. have each recommended Vermilion shareholders vote for all the proposed resolutions at the upcoming annual general meeting of shareholders to be held on May 11.

07:41 EDT Ebix Europe launches ExposureHub platform - Ebix Europe has launched its new platform - ExposureHub, a technology milestone for re/insurance exposure management. The company said, "Developed by in-house exposure management specialists at Ebix, ExposureHub is a versatile and geospatially rich platform powered by state-of-the-art technology and methodologies; providing fast and accurate results and insights that support data-driven risk management decisions while ensuring profitable underwriting. Offering exceptional processing speeds even with huge data volumes, along with interactive global map displays, the platform is module-based and fully configurable, implying that each client and each user gets to use a tool that works best for them. The thoughtful platform layout draws the user into their exposure data - making insights, opportunities and outliers all the easier to identify and act upon."

07:40 EDT Provectus announces USPTO allowed US patent application for use of PV-10 - Provectus announced that the United States Patent and Trademark Office, USPTO, has allowed US patent application 16/688,319, "Composition and Method for Treating Hematologic Cancers," covering the use of PV-10, a formulation of Provectus' immunogenic-small molecule and pharmaceutical-grade rose bengal sodium, RBS, for the treatment of hematologic diseases. In vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls. This allowed patent application will be the first Provectus patent award in hematology from the USPTO. Innovate Calgary, the innovation company of the University of Calgary, is a co-assignee and Aru Narendran, MD, PhD of the University of Calgary's Cumming School of Medicine is a co-inventor on the allowed patent application.

07:38 EDT TC Energy evaluating plan for Crossfield, Alberta hydrogen production hub - TC Energy Corporation (TRP) together with partner Nikola Corporation (NKLA), is evaluating its plan for a hydrogen production hub on 140 acres in Crossfield, Alberta, where the Company operates a natural gas storage facility. The plan will be highlighted during the first-ever Canadian Hydrogen Convention in Edmonton, Alberta. TC Energy expects a final investment decision by the end of 2023; the project will be subject to customary regulatory approvals Nikola will be the hub's anchor customer for its long-haul fuel cell electric vehicles. The southern portion of Alberta is a key transportation corridor for long-haul trucks. TC Energy and Nikola previously announced a joint development agreement with the aim to locate and build hydrogen production hubs in North America. The proposed hub would produce an estimated 60 tonnes of hydrogen per day, with the capacity to increase to 150 tonnes per day in the future. To produce hydrogen, natural gas is reacted in a chemical plant to separate hydrogen and carbon dioxide. The CO2 generated during this process is then captured and sequestered, lowering the emissions to meet clean-energy standards. TC Energy's Crossfield Gas Storage facility, 50 km north of Calgary, holds 68 billion cubic feet of natural gas.

07:37 EDT iSpecimen unveils iSpecimen Marketplace platform - iSpecimen unveiled its iSpecimen Marketplace platform. "The new software includes improved search and supplier data integration capabilities that have been designed to efficiently connect scientists with well-matched samples for their research, as well as help to increase supplier inventory utilization," the company said. "For researchers around the world, obtaining quality specimens in a timely manner has never been an easy feat, and simplification starts with the search function," said Dr. Christopher Ianelli, M.D., Ph.D., iSpecimen Founder and CEO. "Since the Company's inception, demand for our iSpecimen Marketplace continues to grow. As such, we have worked vigorously to continue innovating our search function to streamline access to biospecimens, patients and data that are critical to advancing medical research and delivering results that align with precise banked specimen requirements. We look forward to continuing to make strategic, large-scale investments in the iSpecimen Marketplace that will optimize search results and assist researchers in need of specimens for critical research across the world. This is just the first in a series of developments that will help take biospecimen matchmaking and procurement to new heights."

07:36 EDT Neximmune announces preclinical research collaboration with CUIMC's HICCC - NexImmune announced a preclinical research collaboration with Columbia University Irving Medical Center's, CUIMC, Herbert Irving Comprehensive Cancer Center, HICCC. The research will focus on the use of NexImmune's adoptive cell therapy, AIM ACT, in Columbia's patient-derived organoid, PDO, models of HPV-associated cancers, including head and neck squamous cell carcinoma. "HPV-associated cancers remain an area with a large unmet medical need," said Dr. Jerry Zeldis, Executive Vice President, R&D of NexImmune. "Our collaboration with Columbia University Irving Medical Center will continue to help us develop new therapies for those patients that are not adequately treated and cured with existing standard of care."

07:35 EDT Avadel says 'not aware of any new information' amid recent trading activity - Avadel Pharmaceuticals provided a statement in response to the trading volatility and subsequent brief trading halt of its shares that occurred yesterday. "The company is not aware of any new information, including regarding the ongoing review of the FT218 NDA, that caused yesterday's share price movement and brief trading halt," said Greg Divis, CEO of Avadel Pharmaceuticals. "We are advancing our launch preparations, and look forward to bringing this important treatment to people with narcolepsy."

07:33 EDT Arogo Capital Acquisition, EON Reality enter business combination agreement - Arogo Capital Acquisition announced that it has entered into a definitive business combination agreement with EON Reality, a company in Virtual and Augmented Reality and Knowledge Metaverse industry and education solutions. Upon closing of the transaction, the combined entity, which will retain the name of EON Reality, Inc., will be led by CEO Dan Lejerskar, Founder, Chairman and CEO of the current EON Reality. The companies said, "With over 20-years experience as a solution and thought leader in Virtual and Augmented Reality, EON Reality has grown into a global leader for academic and industry training solutions. EON Reality believes that knowledge is a human right which should be available, accessible, and affordable for every person on the planet! To achieve this goal, EON Reality has developed the de-facto standard for XR education and industry solutions that support devices from mobile phones to head-mounted displays to large-scale screens and even to facilities. As a result of the culmination of years of work with global enterprises and world-class academic institutions, EON Reality's EON-XR serves as the primary product and content delivery vehicle for XR education and industry solutions. Founded around EON Reality's fundamental human right principles that a person should "Learn, Train, Perform," EON-XR contains the backend support and architecture that large organizations need to quickly and efficiently build, deploy, and scale XR applications to supplement their employees' current training and increase productivity efforts." Under the terms of the business combination agreement, EON Reality will combine with a subsidiary of Arogo. and will become a publicly traded entity under the name "EON Reality, Inc." EON Reality will apply to list its common stock under the symbol EOXR and its warrants, if any, under the symbol EOXRW. The transaction implies a proforma company enterprise value of approximately $655M. The transaction is expected to provide EON Reality with approximately $101M in cash proceeds to its balance sheet, assuming no redemptions and before the payment of transactional fees and expenses. The acquisition has been unanimously approved by the board of directors of Arogo. The business combination has also been approved by the board of directors and the majority of shareholders of EON Reality. The transaction is expected to close by the second half of 2022, subject to, among other things, the approval by Arogo stockholders, satisfaction or waiver of the conditions stated in the business combination agreement, and other customary closing conditions, including a registration statement being declared effective by the U.S. Securities and Exchange Commission and approval by Nasdaq to list the securities of the emerged company.

07:32 EDT Travelzoo sees 'higher revenue and profitability in Q2' - The company said, "We currently expect higher revenue and profitability in Q2 2022. We continue to see a trend of recovery of our revenue. However, there could be unexpected fluctuations in the short term. During the pandemic, we have been able to lower our fixed costs. We believe we can keep our fixed costs relatively low in the foreseeable future-while revenue is expected to grow." Q2 EPS/revenue consensus 20c/$20.69M, respectively.

07:29 EDT Great Panther reports P&P mineral reserves up 24% compared to 2020 estimates - Great Panther Mining reports Mineral Resource and Mineral Reserve Estimates for the Tucano Gold Mine in Brazil. The estimates were prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects. The 2021 MRMR has an effective date of July 31, 2021. The 2021 MRMR reflects results of an additional 58,837 metres of drilling up to the end of July 2021, an increased gold price of $1,650/oz for reserves and $1,900/oz for resources, and an exchange rate of BRL 5: USD 1. The 2021 MRMR is focused on the open pit ore zones and reflects changes to the open pit reserves and resources, while the underground will be updated in a future Mineral Resource and Mineral Reserve estimate on completion of engineering studies currently underway. Highlights include: Total Proven and Probable, or P&P, Mineral Reserves are now estimated to be 681,873 gold ounces, of which 371,541 gold ounces are open pit reserves, a 24% increase in P&P open pit reserves since the previously reported MRMR estimate for Tucano with an effective date of September 30, 2020. Total Measured and Indicated Mineral Resources, which are inclusive of Mineral Reserves, now total 1.3M gold ounces, of which 928,000 gold ounces are open pit M&I Mineral Resources, a 65% increase since the 2020 MRMR. The Company completed a 19,000-metre drilling campaign on the Urucum North underground project. Engineering studies are currently underway. Historical reserves will be updated pending these studies.

07:23 EDT Nordic American Tankers sees $51.9M impairment charge for 2021 report - The company said, "No tanker company on Wall Street has the strategy of NAT. NAT does not buy and sell Suezmaxes as a business proposition - the policy is based on the premise to keep the vessels to the end of their lives. Recently prices are up and we have sold a few vessels. In July 2021 we announced a plan to sell ships in combination with buying ships. We have sold four Suezmaxes now, generating a cash injection of about $60M to NAT. Vessel number four was delivered to the new owners on April 12, 2022. We expect that our fleet will grow with the objective of having about 30 Suezmax vessels the next few years. We have informed the market that we receive two newbuildings - one in May and one at the end June this year. They have both achieved contracts of six years each, in total twelve years with first class contractual partners, at solid rates creating earnings and stable cash flow. In light of our recent vessels sales, we have concluded that we should record an impairment charge on our accounts for 2021. This charge is $51.9M related to our vessels built in 2002 and 2003. The impairment charge is a non-cash accounting matter. It has nothing to do with our business as such. We have previously report a year-to-date impairment charge of $8.4M in our 4Q21 Earnings Release. This number will now be adjusted to $60.3M in our 2021 20-F.These accounting matters do not affect our 2022 numbers. The tanker market has developed positively in 2022 and the spot voyage contracts announced lately will contribute significantly to our cash position and ability to pay dividend. NAT is on the way to its objective of becoming debt free."

07:20 EDT Gamida Cell receives FDA clearance for GDA-201 IND, clinical hold removed - Gamida Cell announced that the FDA cleared its investigational new drug, or IND, application and removed the clinical hold for a cryopreserved formulation of GDA-201. GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas. Gamida Cell expects to initiate a company-sponsored Phase 1/2 clinical study in patients with follicular and diffuse large B-cell lymphomas in 2022.

07:17 EDT GXO Logistics releases first ESG report - GXO Logistics announced the release of its first Environmental, Social and Governance, ESG, Report. "Our fresh beginning as a standalone company brings a rare opportunity and responsibility to create a strategy around what matters most to our employees, customers, investors and communities," said Malcolm Wilson, Chief Executive Officer, GXO. "We are committed to making a positive impact for our people, our partners and our planet by harnessing technology to not only improve performance but to minimize our environmental impact, create a safe, welcoming workplace and do business the right way." In 2021, GXO set five environmental goals: 80% global operations using LED lighting by 2025; 80% global landfill diversion rate by 2025; 30% GHG emissions reduction by 2030 vs. 2019 baseline; 50% renewable energy in global operations by 2030; and 100% carbon neutral by 2040.

07:14 EDT JetBlue sees CASM ex-Fuel to increase 15% to 17% year over three - "We are extremely pleased with the demand and revenue momentum, which accelerated throughout the quarter and resulted in first quarter revenue that was roughly six points ahead of our original January forecast; we also executed within the range of our original cost guidance despite abnormally elevated winter weather events. Looking ahead, we are reducing our full-year capacity growth as we work to restore operational reliability and catch up on a backlog of training events, and also as we remain mindful of elevated fuel prices," said Ursula Hurley, JetBlue's Chief Financial Officer. "For the second quarter, we are forecasting CASM ex-Fuel to increase 15% to 17% year over three, reflecting some inefficient, close-in capacity reductions in Q2, frontline premium and incentive pay to support the operation, ramp-up costs to maintain our hiring pace for the summer, and our recently signed deal with Air Line Pilots Association. Our revenue performance for the second quarter is expected to be a record result. However, significantly higher fuel prices and investments in the operation are delaying our return to sustained pre-tax profitability. That said, we believe we are on a path to building back our margins and creating value for our owners through strong revenue growth, disciplined cost control, and a methodical approach to capacity decisions."

07:12 EDT Helius Medical introduces device to US to help MS patients walk - Helius Medical Technologies announced availability in the market of its breakthrough technology with the potential to help patients in the United States with Multiple Sclerosis, MS, who struggle to walk. The technology, known as Portable Neuromodulation Stimulator, PoNS, is now available in the U.S. to help MS patients with gait deficit improve walking ability. PoNS is available commercially by prescription, for the first time, to patients in the U.S. aged 22 and over. "We believe that we are unlocking the full potential of neuromodulation and neuroplasticity to help MS patients walk more steadily and safely," said Antonella Favit-Van Pelt, MD, PhD, Helius's Chief Medical Officer. MS is a progressively disabling condition with the first symptoms appearing in people between ages 20 and 40. "Approximately 40 percent of individuals with MS will need walking assistance within 15 years of the onset of the disease. PoNS therapy provides a unique opportunity for these patients to improve gait functionality and mobility" said Dr. Favit-Van Pelt.

07:08 EDT Air Canada Selects Pratt & Whitney GTF Engines for Airbus A320neo aircraft - Pratt & Whitney, a division of Raytheon Technologies (RTX) and Air Canada have announced the selection of Pratt & Whitney GTF engines to power 30 firm and 14 purchase right Airbus (EADSY) A321XLR aircraft. Pratt & Whitney will also provide Air Canada with engine maintenance through an EngineWise Comprehensive service agreement. The first aircraft is expected to be delivered in the first quarter of 2024.

07:07 EDT Nielsen expands Smart TV data deal with Vizio - Nielsen (NLSN) and VIZIO (VZIO) announced a multi-year agreement that provides Nielsen with precise glass-level viewership data powered by Inscape Smart TV data. The deal includes a period of exclusivity for data gathered on an expanded roster of 400 local stations that will be processed around the clock by Inscape's systems. Nielsen, which licensed Inscape for national addressable measurement starting in 2021, now has the rights from VIZIO to integrate Inscape data in both its local and national audience measurement solutions. Through this agreement, Nielsen can now add big data from a pool of approximately 20 million Smart TVs, a key enhancement that includes incremental coverage for 400 stations across local U.S. markets that currently include Local People Meter, Set Meter and Portable People Meter panels.

07:07 EDT Synlogic announces data presentations from five programs at SEED conference - Synlogic announced its planned presentations at the 2022 Synthetic Biology: Engineering, Evolution & Design, SEED, conference being held May 2-5, 2022, in Arlington, VA. The oral presentation outlines Synlogic's progress in developing Synthetic Biotic drug candidates for rare metabolic diseases phenylketonuria, PKU, and homocystinuria, HCU, both inborn errors of metabolism. "The preclinical and clinical data being presented at SEED this year represent the remarkable progress we have achieved through our Synthetic Biotic programs to date in multiple therapeutic categories," said Synlogic's Chief Scientific Officer David Hava, PhD. "These presentations highlight the breadth and versatility of Synlogic's application of synthetic biology to biotherapeutics, by targeting GI-based metabolites across different diseases to provide meaningful new treatment options with the potential to address important medical needs." Oral Presentation: Title: "Engineered E. coli Nissle for the Treatment of Inborn Errors of Amino Acid Metabolism." Poster Presentations: Title: "Engineering E. coli Nissle 1917 to Consume Uric Acid in the GI Tract." Title: "A Synthetic Biotic, SYNB8802, Lowers Urinary Oxalate in Preclinical Models and Healthy Volunteers with Induced Dietary Hyperoxaluria." Title: "Biosensor-Enabled Optimization of SYNB1934, a Synthetic Biotic for Phenylketonuria Demonstrating Clinical Efficacy." Title: "Development of SYNB1353, A Synthetic Biotic Engineered to Consume Methionine for the Treatment of Homocystinuria." Title: "Local Delivery of Synthetic Biotics to Treat Inflammatory Bowel Disease." Date and Time: May 2, 2022 from 4:00-5:00 PM ET (Poster session A)

07:05 EDT First Commonwealth increases quarterly dividend 4.3% to 12c per share - First Commonwealth Financial Corporation declared a common stock quarterly dividend of $0.12 per share, which represents a 4.3% increase from the previous quarter. The cash dividend is payable on May 20, 2022 to shareholders of record as of May 6, 2022. This dividend represents a 3.3% projected annual yield utilizing the April 25, 2022 closing market price of $14.41.

07:04 EDT Marker Therapeutics announces entry into services agreement with Wilson Wolf - Marker Therapeutics announced it has entered into a services agreement with Wilson Wolf Manufacturing Corporation. The agreement includes an $8M upfront cash payment by Wilson Wolf to Marker in exchange for services relating to Marker's expertise in the manufacture of cell therapies. Wilson Wolf has agreed to pay Marker an additional $1M if the certain work, as defined in the services agreement, is completed within one year from the onset of the services agreement. "Marker Therapeutics has created its own cGMP manufacturing capacity that allows us to service our clinical trials with full control and lower costs when compared to use of contract manufacturing organizations," said Peter Hoang, CEO of Marker Therapeutics. "Our process utilizes Wilson Wolf products and we think our knowledge is highly aligned with Wilson Wolf's mission to advance the cell and gene therapy field through simplified manufacturing. Wilson Wolf's payment of $8 million in non-dilutive funding, with potential for another $1 million, for a portion of Marker's knowledge will be used by Marker to advance its mission to fundamentally improve the way liquid and solid tumors are eliminated. Given how entrenched Wilson Wolf's technology is in the cell and gene therapy field, we see this as an endorsement of Marker's manufacturing expertise."

06:58 EDT Raytheon Technologies reports backlog at end of Q1 of $154B - Backlog at the end of the first quarter was $154B, of which $92B was from commercial aerospace and $62B was from defense.

06:56 EDT International Game receives G4 responsible gaming accreditation - International Game announced that it has become the first U.S. supplier in the gaming industry to receive Global Gambling Guidance Group, or G4, responsible gaming accreditation for its sports betting operations. With this monumental achievement from G4, IGT is certified in responsible gaming across its four product segments encompassing lottery, gaming, digital and betting.

06:53 EDT Ring Energy reports Q1 sales volumes of 8,870 Boe/d - Ring Energy provided an operational and financial update for the Company's Q1 sales, drilling program and further debt repayment. Highlights include: Q1 sales volumes of approximately 8,870 barrels of oil equivalent per day, or Boe/d, which was above the high end of Q1 guidance; Improved sales were driven by several factors such as placing wells on production sooner than anticipated and production optimization with field compressor installs that led to an overall increase in gas sales; Generated free cash flow for the 10th consecutive quarter and paid down an additional $10M in debt in the Q1; Increased liquidity at March 31 to approximately $71M; Decreased total outstanding debt balance to $280M; Benefitted from increased commodity prices with the majority of its low-price legacy oil hedges expiring at year-end 2021 and no natural gas price hedges in place in 2022; Drilled six wells, four Central Basin Platform and two Northwest Shelf during the Q1 as well as completed and placed on production four CBP wells; and performed four conversions from electrical submersible pumps to rod pumps, or CTR, in the Q1, all in the NWS. Paul McKinney, CEO, commented, "We are pleased with our Q1 results. Our operations teams continue to perform efficiently and effectively maintaining our base production and bringing on new development wells ahead of schedule. The combination of stronger than anticipated sales, improved commodity prices, and our continued focus on driving cost efficiencies enabled us to not only generate free cash flow for a 10th consecutive quarter, but also allowed us to pay down $10M, in debt during the quarter. In addition to drilling and completion efficiencies, we continued our successful CTR program by performing four conversions. Our performance this quarter establishes a solid foundation for 2022 and encourages us to continue executing on our value-focused, proven strategy."

06:50 EDT CNX Resources, Evolution Well Services announce four-year contract extension - CNX Resources and Evolution Well Services announced a four-year extension of their current partnership. In 2018, Evolution and CNX began negotiating a long-term agreement to utilize Evolution's 100% electric, natural gas-fueled, gas turbine-powered fracturing fleets for strategic basin development. Those negotiations yielded the first long-term contract in the Appalachian basin for this game-changing technology.

06:46 EDT Valero expects DGD project to commence in 4Q22 - The DGD project located next to Valero's Port Arthur refinery, which is expected to have a renewable diesel production capacity of 470M gallons per year, is now expected to commence operations in the fourth quarter of 2022, versus the prior estimate of the first quarter of 2023. The total annual DGD production capacity is expected to increase to approximately 1.2B gallons of renewable diesel and 50 million gallons of renewable naphtha. "We expect low-carbon fuel policies to continue to expand globally and drive demand for low-carbon fuels," said Gorder, "and with that view, we are leveraging our operational and technical expertise to steadily expand our competitive advantage." BlackRock and Navigator's large-scale carbon sequestration project is expected to begin startup activities in late 2024. Valero is expected to be the anchor shipper with eight of Valero's ethanol plants connected to this system, producing a lower carbon intensity ethanol product to be marketed in low-carbon fuel markets that is expected to result in a higher product margin. Refinery optimization projects that are expected to reduce cost and improve margin capture are progressing on schedule. The Port Arthur Coker project, which is expected to increase the refinery's utilization rate and improve turnaround efficiency, is still expected to be completed in the first half of 2023.

06:39 EDT D.R. Horton lowers 2022 homes closed view 88,000-90,000 - Previous view 90,000-92,000. Sees Income tax rate of approximately 24%; Outstanding share count at the end of fiscal 2022 approximately 3% lower than at the end of fiscal 2021. The Company plans to also provide guidance for its third quarter of fiscal 2022 on its conference call.

06:37 EDT Verve Therapeutics presents new findings from study of VERVE-101 - Verve Therapeutics announced new findings from a comprehensive off-target assessment of its lead product candidate, VERVE-101, demonstrating minimal to no off-target editing and supporting the favorable tolerability profile observed across multiple non-human primate studies conducted to date. The data will be presented at the Precision Genome Engineering Keystone Symposia in Keystone, Colorado on April 29. Extensive additional evaluation in non-target cells and in other cellular contexts identified only two potential sites with statistically significant editing above untreated controls in any cell type and with any batch. The two instances of off-target editing occurred at doses greater than those expected to achieve saturation for on-target editing. Based on these data, Verve believes that VERVE-101 has a low risk of off-target genomic modifications that would be expected to have an associated clinical adverse effect. In addition, in order to assess for potential guide-independent off-target effects on a genome-wide scale, a whole genome sequencing analysis of human liver cells treated with VERVE-101 was performed at a very high coverage depth of 500 sequencing reads per base. This analysis demonstrated no increase in adenine editing compared to untreated controls. Finally, in order to assess for genomic integrity, including chromosomal rearrangements and large insertions or deletions, Verve researchers performed whole genome optical mapping in primary human liver cells and observed no additional structural variants after VERVE-101 treatment when compared with untreated controls. "Based on our interactions with regulatory agencies and as part of our clinical development path for VERVE-101, we have conducted rigorous analyses to ensure that we are advancing a therapy predicted to be both effective and safe," said Andrew Bellinger, M.D., Ph.D., chief scientific and medical officer of Verve. "These updated findings, leveraging industry-leading and highly sensitive off-target analysis tools, continue to demonstrate minimal to no off-target editing and support our plans to initiate global clinical development with VERVE-101 for later this year."

06:33 EDT Helix Energy sees FY22 CapEx $45M-$55M - Capital additions during Q1 approximated $11M and are expected to be $34M-$44M for the remainder of 2022. Expects to continue anticipated momentum from second half 2022 into 2023. Sees improved operating cash flows in 2023 compared to 2022. Comments taken from Q1 earnings conference call presentation slides.

06:30 EDT UBS sees repurchasing around $5B of shares during 2022

06:27 EDT GE: Healthcare order demand strong, monitoring China - Comments taken from Q1 earnings conference call presentation slides.

06:24 EDT General Electric 'on track' to launch three independent companies, says CEO Culp

06:23 EDT General Electric reports Q1 total orders $18.9B, organic orders up 13%

06:18 EDT Armada Hoffler closes sale of Summit Place in Charleston - Armada Hoffler Properties successfully completed its strategic exit from the student housing space by closing the sale of Summit Place in Charleston, South Carolina. The disposition of the student housing property marks the final sale in the asset class, underscoring the Company's broader strategy to focus on conventional apartment communities when acquiring or developing multifamily assets. Completed by Armada Hoffler Properties in the Q3 of 2020 at the corner of Spring and Lee streets, Summit Place is a five-story building with 357 beds and an amenity offering on par with Class A conventional apartment communities.

06:14 EDT Spirit AeroSystems signs repair center agreement with GAMECO - Spirit AeroSystems (SPR), announced an agreement with Guangzhou Aircraft Maintenance Engineering Company, or GAMECO, to be the Spirit Authorized Repair Center in Mainland China. GAMECO was founded in 1989 as a joint venture of China Southern Airlines, Hutchison A/C Maintenance Investment and South China International A/C Engineering. Initially, GAMECO will provide repair services to replace Boeing (BA) 757 RB211 inlet cowlings and A330 Trent inlet cowlings with plans to expand into nacelle work for Spirit customers. Spirit has signed agreements with two freight carriers to place 757 inlet cowling work with GAMECO. In February, Spirit signed a contract with YTO Cargo Airlines, based in Hangzhou, China; and in September 2021, Spirit signed a 10-year agreement with SF Airlines, a cargo carrier based in Shenzhen, China.

06:13 EDT Uber to pay fine in Australia for misleading users on cancellation charges - The ACCC has instituted proceedings in the Federal Court against Uber, which has admitted it engaged in misleading or deceptive conduct and made false or misleading representations in the Uber ridesharing app. Uber has admitted that it breached the Australian Consumer Law by making false or misleading statements in cancellation warning messages and Uber Taxi fare estimates, and has agreed to make joint submissions with the ACCC to the Court for penalties totaling $26M to be imposed. Between at least December 2017 and September 2021, the Uber rideshare app displayed a cancellation warning to consumers who sought to cancel a ride saying words to the effect of 'You may be charged a small fee since your driver is already on their way', even when consumers were seeking to cancel a ride within Uber's free cancellation period. The parties have agreed to jointly seek orders from the Federal Court including declarations that Uber contravened the Australian Consumer Law, and for Uber to pay $26M in penalties. The Federal Court will decide at a later date whether the orders sought, including the proposed penalties, are appropriate. Reference Link

06:06 EDT Jack Dorsey: Taking Twitter private the 'correct first step' - Former Twitter CEO Jack Dorsey says taking Twitter private "is the correct first step" and that Elon Musk's goal to create a "maximally trusted and broadly inclusive" platform "is the right one." Dorsey tweeted: "In principle, I don't believe anyone should own or run Twitter. It wants to be a public good at a protocol level, not a company. Solving for the problem of it being a company however, Elon is the singular solution I trust. I trust his mission to extend the light of consciousness." Reference Link

05:25 EDT Vaalco Energy announces completion of Avouma 3H-ST development well - Vaalco Energy announced the completion of the Avouma 3H-ST development well that was drilled from the Avouma platform in the Etame field, offshore Gabon. The initial flow rate of the well was approximately 3,100 gross barrels of oil per day, or BOPD, which was above VAALCO's internal expectations. This sidetrack well targeted existing high-quality Gamba hydrocarbons at the top of a structure that have not previously been produced by prior wells. This is the second successful well of Vaalco's 2021/2022 drilling campaign.

05:11 EDT Amazon, Salvatore Ferragamo report belt counterfeiter to MSA in China - Amazon (AMZN) announced that its Counterfeit Crimes Unit, or CCU, worked closely with Salvatore Ferragamo (SFRGY) to report a counterfeiter of Ferragamo's Gancini belt to the Market Supervision and Administration, or MSA, authorities located in Yiwu City, Zhejiang Province, China. Following an investigation by the MSA and Amazon's CCU, officials raided the criminal's warehouse, seizing hundreds of counterfeit belts and buckle accessories that may otherwise have been sold through retail channels around the world. Amazon and Ferragamo will continue to assist law enforcement in investigating counterfeiters and preventing their products from entering the global supply chain, to help stop this illicit trade at the source.